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In the study of cellular RNA chemistry, a major thrust of research focused upon sequence determinations for decades. Structures
of snRNAs (4.5S RNA I (Alu), U1, U2, U3, U4, U5, and U6) were determined at Baylor College of Medicine, Houston, Tex,
in an earlier time of pregenomic era. They show novel modiﬁcations including base methylation, sugar methylation, 5 -cap
structures(types0–III)andsequenceheterogeneity.Thisworkoﬀeredanexcitingproblemofposttranscriptionalmodiﬁcationand
underwent numerous signiﬁcant advances through technological revolutions during pregenomic, genomic, and postgenomic eras.
Presently,snRNAresearchismakingprogressesinvolvedinenzymologyofsnRNAmodiﬁcations,molecularevolution,mechanism
of spliceosome assembly, chemical mechanism of intron removal, high-order structure of snRNA in spliceosome, and pathology of
splicing. These works are destined to reach ﬁnal pathway of work “Function and Structure of Spliceosome” in addition to exciting
new exploitation of other noncoding RNAs in all aspects of regulatory functions.
1.Introduction
A key element in the study of cellular RNA metabolism is
themolecularcharacterizationofRNA.Thischaracterization
requires accurate determination of the RNA sequence. It
is imperative to understand how RNA structure comple-
ments the functional deﬁnition of RNA. Cellular RNAs
are posttranscriptionally modiﬁed at various points in the
primary RNA transcript as well as processed. In cellular RNA
metabolisms,RNAmaturationisperformedthroughvarious
structural alterations that include chemical modiﬁcations of
constituent components. A most representative modiﬁcation
is observed in chain shortening, rearrangements by transfer
of phosphodiester linkages involved in splicing mechanisms
(pre-mRNA), deletions (pre-rRNA), and transsplicing (try-
panosomal mRNA). Another is chain expansion demon-
strated by modiﬁcations observed on polyadenylation, U-
addition at 3  ends, 5 -cap formation at 5  ends, and inser-
tions within trypanosome RNA. Other examples of mod-
iﬁcations are base modiﬁcations, such as deaminations,
methylations, hypermodiﬁcations, and ribose methylations.
The most modiﬁed RNAs are tRNAs containing approx-
imately 2–22 modiﬁed nucleotides per molecule of ∼75
nucleotide length, and there have been more than 130 dif-
ferent signature modiﬁed nucleotides reported [1]. The dis-
covery of snRNA and m3
2.2.7G caps occurred within the last
50 years. They also contain their own speciﬁc modiﬁed nu-
cleotides such as Ψ,m 6A, m2G, and 2 -O-methylated nu-
cleotides (Table 1).
The next class is the ribosomal RNAs which contain
204–209 modiﬁed nucleotides within 18S (1,869nt) + 28S
(5,035nt) RNA in eukaryotes. The mRNAs contain the least
modiﬁed nucleotides, with the exception of the 5  end cap
structure and occasional m6A in the molecule.
In ensuing years, massive scale DNA sequencing was ad-
vanced to accommodate the “Human Genome Project.” Two
groups published the genomic map where the coding genes
were cataloged. It was conservatively estimated that there are
25,000 genes and 50,000 proteomes involved in cell meta-
bolism. It was also envisioned that processing mechanisms
could be discerned by comparing the genomic structure with
the RNA sequence determined using cDNA methods. Based2 Journal of Nucleic Acids
Table 1: Signature sequences and modiﬁcations of major snRNAs. The 5  cap and 3  nucleosides, base modiﬁed nucleosides, and alkali
resistant oligonucleotides were determined by many methods described in the text. The table provides a summary of individual RNA
characteristics of rat Novikoﬀ hepatoma cells.
RNA Subspecies Localization 5  End 3  End Modiﬁed Nucleotides
4.5S RNA
I Extranucleolar nuclei pppG U-OH
II (U6) Extranucleolar nuclei mpppG U-OH
3Ψ,m 6A, m2G, AmA,
AmG, AmGmC,
CmC, CmA, CmCmU
III Extranucleolar nuclei pA Um AmA, GmA, 2GmG,
m2G, m6A, 3Ψ
5S RNA
I Nucleoli, nuclei and
cytoplasm pppG U-OH
II Nucleoli, nuclei and
cytoplasm pppG U-OH
III (U5) Extranucleolar nuclei m3
2,2,7GpppAmUmAC U-OH
A-OH UmU, GmC, 2Ψ
U1 RNA U1a (5.8S RNA) Nucleoli and
cytoplasm pC, pG U-OH UmG, GmC, Ψ
U1b, U1c Extranucleolar nuclei m3
2,2,7GpppAmUmAC U-OH,
G-OH AmC, 2Ψ
U2 RNA Extranucleolar nuclei m3
2,2,7GpppAmUmC C-OH
A-OH
GmGmC, GmG,
GmA, m6AmG,
CmΨ,U m A ,C m U ,
13Ψ,( m 6A, m2G)
U3 RNA U3a, U3b,
U3c, U3d Nucleoli m3
2,2,7GpppAmA(m)AG
A-OH,
U-OH,
C-OH
2Ψ
on the ever-increasing number of RNA sequences, it was
determined that most coding RNAs mature as a result of
alternative splicing. Aberrant splicing is attributed to point
mutations in the genetic code and splicing code [2]. It is
noted that RNA sequencing can aid the determination of the
molecular pathogenesis of diseases.
2. HistoricalVentureof RNA Research
Detailed nucleic acid chemistry began with discoveries of the
DNA helix by Watson and Crick [3] and DNA polymerase
by Lehman et al. [4, 5]. With DNA being the genetic material
providing a blue print for living creatures, it moved genomic
era thinking away from the earlier notion that protein,
carbohydrate, and lipid were the only essences of living
things.
DNA is there to provide information needed to build the
cells, tissues, organs, and whole individuals. It took a long
time to move from the histochemical presentation of DNA
in the nucleus and RNA in the nucleolus and cytoplasm
[14] to the isolation of nucleoli, nuclei, mitochondria and
ribosomes, facilitating the elucidation of their components,
their structures, and their functions. Even within the same
species, no two individuals are identical. Disarray in DNA
structure can determine whether one is healthy or diseased.
In the quest to conquer cancer, diﬀerences in cellular
morphology and uncontrolled growth became and remain
a major research consideration when one compares normal
cells with cancerous cells and tissues. Cancer cells with pleo-
morphic, hypertrophic nuclear, and nucleolar morphology
remain a useful pathological criterion for a cancer diagnosis.
TheinformationwithingenesistransferredtoRNAandthen
to proteins made on ribosomes that deﬁne a cell phenotype.
The fractionation of cells into various components includes
nucleoli, nuclei (Figure 1), ribosomes, mitochondria, cytosol
and others.
The main interest among these compartmental compo-
nentswastheRNA.TheRNAhasitsownexclusiveproperties
which are not found in DNA.
The discovery of RNA polymerase I in the nucleoli
[31] is the landmark of RNA research in these cellular
compartments. It was not until 1968, with the introduction
ofgelelectrophoresisintoRNAresearch[32],thatsubspecies
of 4–8S RNAs could be separated from high-molecular-
weight RNAs (>18S RNA). Until then, the 4–8S RNAs were
considered as tRNAs and their precursors. Diﬀerent from
the prokaryotic cells, eukaryotic cells were shown to have
a variety of small RNAs in their nuclei (Figure 2). These
RNAs used to be called LMWN RNA (low-molecular weight
nuclear RNA) and now the name is uniﬁed as snRNA (small
nuclear RNA).
These include U1 RNA, U2 RNA, U3 RNA, (named as
such because these RNAs contain a high proportion of
uridylic acid), 5S RNA III (U5 RNA), 4.5S RNA I (Alu RNA),
4.5S RNA II (U6), and 4.5S RNA III. All of these snRNA
species and many more have been sequenced and their func-
tionselucidatedinpre-rRNAprocessing[33]andpre-mRN A
splicing [34, 35].Journal of Nucleic Acids 3
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Figure 1: Nuclear and nucleolar morphology. Normal rat liver nuclei have 1–6 round nucleoli which are less than 2μm in diameter. In
regenerating liver, cells contain enlarged nucleoli. In tumor cells (hepatocellular carcinoma), the nucleoli are not only enlarged but also they
become pleomorphic in morphology. Nuclei were isolated by homogenization in 2.3–2.4M sucrose containing 3.3mM CaCl2. Nuclei were
sonicated in 0.34M sucrose and layered on 0.88M sucrose for puriﬁcation by centrifugation. Isolated nuclei and nucleoli had high purity,
and morphologies were well preserved [6].4 Journal of Nucleic Acids
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Figure 2: Polyacrylamide gel electrophoretic separations of nuclear 4–7S RNAs of rat liver and Novikoﬀ hepatoma cells [7]. (a) The 8% gel
electrophoretic patterns of4–7S RNA fromvarious cell organelles ofrat liver. The gel was stained with methylene blue for RNA visualization.
(1) Nuclear 4–7S RNA, (2) ribosomal 4–7S RNA, (3) mitochondrial 4–7S RNA, and (4) soluble cytoplasmic sap 4–7S RNA. (b) The 10%
slab polyacrylamide gel electrophoretic separation of [32P]-labeled 4–7S RNA from Novikoﬀ hepatoma cell nuclei. The gel was autographed
with X-ray ﬁlm.
Table 2: Characteristics of RRM/RNP/RBD domain.
(1) ∼90–100 amino acids domain and most abundant in vertebrates
(2) Many RNA binding proteins contain more than one RRM
(3) Contain 2 conserved RNP1 (RGQAFVIF in β3) and RNP2 (TIYINNL in β1) in 4 antiparallel β-sheets of βαββαβ-fold
(4) Binds 2–8 nucleotides of RNA (2 in CBP20, nucleolin and 8 in U2B
  )
(5) A typical RRM containing 4 nucleotide binding sites (UCAC)
(6) 3 conserved aromatic amino acids (Y, F, W, H or P) in central β-strands (2 in RNP1 of β3a n d1i nR N P2i nβ1)
(7) 2 RRMs in a protein are separated by small linker and provide a large RNA binding surface or RNA binding surface point away
from each other
(8) RNA bases are usually spread on the surface of protein domains while the RNA phosphates point away toward the solvent
(9) Binding surface of the protein is primarily hydrophobic in order to maximize intermolecular contact with the bases of the RNA
(10) Few intramolecular RNA stacking and many intermolecular stacking mediated by aromatic amino acids
(11)
RNA recognition is a two-step process, in which any RNA is attracted approximately equally well. However, if stacking and
hydrogen-bond interactions that “lock” the interaction cannot be properly established, the complex redissociates quickly (large
koﬀ), which results in overall weak aﬃnity for RNA oligonucleotides of the wrong sequence
(12)
Many ssRNA binding proteins recognize RNA in the loop (stem-loop) better than in ssRNA (kon ∼ 3 fold & koﬀ ∼ 590 fold,
therefore, overall aﬃnity ∼2000 fold diﬀerences) due to higher entropy loss with ssRNA binding than stem-loop binding and
stabilizing interactions of stem
The most interesting discoveries in the midst of
sequencing were the very unusual trimethylguanosine cap
structure in U1 RNA (m3
2,2,7GpppAmUmAC), U2 RNA
(m3
2,2,7GpppAmUmC), U3 RNA (m3
2,2,7GpppAmA(m)-
AGC), and 5S RNA III (U5 RNA) (m3
2,2,7GpppAmUmAC)
[36]. Afterwards, myriads of cap structures in viral RNA and
mRNA were discovered [37].
The history of RNA sequence work has occurred in three
eras. The pregenomic era was devoted to the small RNAs and
commenced with the sequence of large RNAs as technology
developed for cDNA synthesis, ampliﬁcation, cloning, and
sequencing. The DNA technology was explosive and paved
the way toward establishment of sequence technology not
only for RNA and cDNA but also for genomic DNA.
In addition to sequence study, the secondary and tertiary
structures have also been determined. A representative study
was the crystallographic study of RNA-protein interactions.
For example, the most well-worked-out motif is RRM (RNA
recognition motif) which is most abundant in hnRNP [40]
and splicing factors [41]. The summary of characteristics of
RRM is in Table 2.
It has been known for a long time that pre-mRNA
(hnRNA) is cotranscriptionally assembled into beads on a
string consisting of 30–50S (20–30nm) particles [42]. TheJournal of Nucleic Acids 5
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Figure 3: The supraspliceosome model from the article by Sperling et al. [8]. (a) It was stated that pre-mRNA which is not being processed
is folded and protected within the native spliceosome. (b) With diﬀerent staining protocol, it was possible to visualize the RNA strands and
loops emanating from the supraspliceosome. These complexes were found to contain hnRNP proteins (personal communication).
RNP (hnRNP) has usually 48hnRNP proteins and ∼700–
800 nucleotide long RNA string [43]. More recently, most
hnRNP proteins have been found to have 1-2 RRM motifs
for RNA binding. From these characteristics, the primary
RNA transcripts have been folded from the 5  end with the
following rules: a minimum of 3 nucleotides in the loop and
a minimum of 3 base pairs at the stem. According to stacking
and loop energy rules, two nucleotide loops cannot exist.
The number of base pairs needed for stabilization with the
most stable stacking energies by CCC/GGG or GGG/CCC is
3 base pairs with −9.8kcal and the highest loop destabilizing
energy is +8.4kcal [44]. In addition, protein binding to
RNA has been shown to have − G≈10−13Kcal/mol [45]
which can overcome the loop destabilizing energies of any
size. With this rule, folding the hnRNA in GC, AU, and
GU pairings was carried out as the RNA was transcribed,
extending contiguous base pairing until it comes to a base
pair mismatches. Accordingly, small simple RNA hairpins
have been constructed with the aid of a computer [46]f r o m
the 5  end (transcription start sites). Consensus patterns for
folding characteristics have been observed (Table 3).
The transcripts form one stem loop for every 15–18
nucleotides which is consistent with ∼15–17 nucleotides per
hnRNP protein (700–800 nucleotides per 48hnRNPs in one
hnRNP particle) reported earlier [43]. The thermodynamics
of RNA folding was consistent with the order of splicing
in ovomucoid pre-mRNA [47]. From the point of view
that supraspliceosomes contain hnRNP proteins (personal
communication), it may be that this cotranscriptional for-
mation of hnRNP string particles [47–49]m a yc o n t r i b u t et o
a role in the formation of supraspliceosomal RNP (Figure 3)
[8].
The postgenomic era is the present day era or the second
generation genome era. With the recent discovery that there
Table 3: Frequency of stem loops in primary pre-mRNA tran-
scripts. The simple stem loops with minimal 3 nucleotides in the
loopandminimal3basepairsinthestemconsistingofAU,GC,and
GU pairs have been constructed with the aid of a computer [46].
The total number of nucleotides were divided by numbers of stem
loops for frequency. The number of nucleotides in each loop and
each stem and spacer were counted and averages were calculated.
(1) Human insulin gene transcript: 1,430nt. (2) Human HDHGT
(25-hydroxyvitamin D3 1-α-hydroxylase gene transcript): 4,825nt.
(3) Human FMR1 (fragile mental retardation 1) gene transcript:
39,224nt. (4) Chicken ovomucoid gene transcript: 6,067nt.
Transcript nt/loop nt/stem nt in
spacer Frequency
(1) Insulin 4.6 7.4 3.5 15.5
(2) HDHGT 5.8 7.0 4.9 17.6
(3) FMR1 5.0 6.8 3.4 15.3
(4) Ovomucoid 5.6 7.0 3.7 16.0
is a paradox [50, 51] in the cellular transcript number,
which is 2-3-fold in excess and that 50% of the cellular
transcriptsarencRNAs,thesecondgenerationgenomicerais
in the process of resequencing the genome for ncRNAs. It is
anticipated that there will be a revision in the ﬁrst generation
genomic picture. In this era, work is proceeding that will
probe and dissect the RNA metabolism in which aberrant
processing should be elucidated by RNA sequencing. To
dissect the molecular pathology of RNA metabolism, it is
also necessary to study higher-order structures based on the
sequencestudiesinvolvedintheassemblyofmacromolecular
machinery. It is natural to hope that therapeutic interven-
tions will be discovered that can correct errors in the genetic
code and its product splicing.6 Journal of Nucleic Acids
Table 4:ParadoxicalcharacteristicsofncRNAsinhumansandmice[50,51].Theexcessivenumberoftranscriptsthananticipatedfor25,000
genes indicates that the ncRNAs which were not detected due to scarce abundance have been detected by more sensitive methods. Some of
these characteristics are summarized.
Human Mouse
Gene Number 75,000, 84,000 or 140,000 (cDNA identiﬁed)
Transcripts 181,000
Population 50% Poly-A RNAs (of 16% genome)
50% transcripts
(of 62% genome)
(35% from antisense strand)
Intron 30% genome
Processing Polyadenylation, 5  cap, splicing, nucleotide modiﬁcation
Transcripts from Intergenic, Intronic regions and antisense strand
Short ncRNAs
miRNA, siRNA (tasiRNA, natsiRNA), piRNA, rasiRNA (pitRNA), PARs (PROMTs,
PASRs, TSSa-RNAs, tiRNAs), MSY-RNA, snoRNA, sdRNA, moRNA, tel-sRNA,
crasiRNA, hsRNA, scaRNAs, AluRNA, YRNA, tRNA-derived RNAs
Long ncRNA (lncRNA)
(0.5–100kb)
Cancers, disorders in skin, heart, brain, cerebellum, and so forth. TR/TERC, NEAT
RNA (NEAT1v-1, NEAT1v-2, NEAT2/MALAT1), PINC RNA, DD3/PCA3,
PCGEM1, SPRY4-1T1, xiRNAs (Xist RNA, Tsix RNA, RepA RNA), AIR, H19,
KCNQ1ot1, HOTAIR, BORG, CTN RNA, ANRIL RNA, LINE, CSR RNA, satellite
DNA transcripts and so forth
Function Regulatory function in all aspects of metabolism [52]
The RNAs have been classiﬁed according to the following
diverse basis of criteria:
(i) cell biology: cell types, subcellular origins,
(ii) molecular weight: high molecular weight (HMW)
and low molecular weight (LMW/small),
(iii) S value: 5S rRNA, 7S RNA, 18S RNA, and others,
(iv) linearity: linear, cyclized, and branched (Y shaped),
(v) metabolism: precursor, processed intermediates, and
mature,
(vi) standard: hnRNA, rRNA, mRNA, tRNA, and ncRNA
(snRNA, snoRNA, miRNA, and others as in Table 4).
3. Preparationof RNA from Isolated
SubcellularCompartments
RNA can be extracted from puriﬁed nucleoli, nuclei, ribo-
somes, mitochondria, and cytosol by the SDS-phenol proce-
dure. The procedure involves the suspension of organelles in
0.3–0.5% SDS (sodium dodecyl sulfate), 0.14M NaCl, and
0.05M sodium acetate buﬀer at pH 5.0 and deproteinization
by phenol containing 0.1% 8-hydroxyquinoline at 65◦C
[53]. The extracted RNA is precipitated with 2–2.5 volumes
of ethanol containing 2% potassium acetate. The RNA is
washedbyethanolanddissolvedinappropriatebuﬀerforthe
analysis. The DNA and protein contaminations are less than
3% by weight. The puriﬁed RNA is separated into individual
RNA species using sucrose density gradient centrifugation,
gel electrophoresis, and column chromatography [38].
4. Structure Determination
4.1. Structural Characteristics of Various RNAs Bearing Sig-
nature Sequences and Modiﬁcations. The RNA is composed
of basic 4 nucleosides of guanosine, adenosine, uridine, and
cytidine linked by 5 -3  phosphodiester bonds between two
ribose moieties. In addition, some of these nucleotides are
modiﬁed in base as well as in ribose moieties and contain
unusual pyrophosphate bonds at their 5  ends and 2  O-
methylated 3  end.
Mature RNAs are synthesized in the nuclei and directed
by the posttranscriptional processing machineries. Because
of these speciﬁc modiﬁcations, there is a general consensus
on the presence of speciﬁc signature sequences and modiﬁ-
cations for the identity of RNA classes. Based on extensive
sequence work, it is possible to classify RNAs according
to structural modiﬁcations. Figure 4 provides an outline
for characteristics of RNA, and its modiﬁcations and brief
examples are given in Table 5.
4.2. General Scheme of RNA Sequencing. The very ﬁrst RNA
sequence was obtained from the work of yeast alanine
tRNA in 1965 [54]. In this work, the prerequisites for RNA
sequence work were developed and described. Since then,
it is a fundamental approach to establish oligonucleotide
catalogs using speciﬁc RNases. One set is the catalog of
T1 oligonucleotides produced by RNase T1. The other is
the catalog of oligonucleotides produced by RNase A. The
analytical method was based on UV spectral absorption in
the earlier years. Subsequently, since 1970, isotopic labeling
methods were widely used which are 1,000-fold more
sensitive. Furthermore, many other improvements in RNAJournal of Nucleic Acids 7
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Figure 4: Summary of RNA modiﬁcations. Cotranscriptional and posttranscriptional RNA modiﬁcations are summarized.
Table 5: Examples of modiﬁcation. All RNA species including
high- and low-molecular-weight RNAs have their own signature
sequences and modiﬁcations.
RNA Sequence and signature modiﬁcation
hnRNAs
(Exons + Introns)
m7Gc a p ,m 6A, Poly-A,
splicing codes
mRNAs
(mainly exons)
m7Gc a p ,m 6A, Poly-A
Editing (C→U&A→I)
tRNAs TΨC, CCA,
Many hypermodiﬁed bases
45S pre-rRNA Repeated U sequences at 5  end spacers
18S rRNA m2
6A, hypermodiﬁed m1acp3Ψ
28S rRNA NmNmNmN, NmNmN
snRNAs, snoRNAs
m3
2,2,7Gc a p ,m γGc a p
Types I, II, and III caps by ribose
methylations
mRNA
(Trypanosome)
m7Gpppm2
6,6AmpAmpCmpm3UmpAp
Insertion of repeated U sequence
Deletion of U sequence
sequence technique have made it possible to advance the rate
of RNA sequence work greatly (Table 6).
Improvement was observed in the following areas:
(1) RNA labeling techniques, (2) fractionation procedures
(chromatography, electrophoresis, and gel procedures), (3)
use of various RNases, (4) contig seeking, and (5) ladder
sequence gel analysis. For example, based on labeling at the
5 -end with [32P]-γ-ATP by polynucleotide kinase [56], it
has become feasible to read a 150 nucleotide sequence using
an endonuclease assisted ladder gel from the 3 -end. Also,
based on labeling at the 3 -end with [32P]-5 -pCp by RNA
ligase [57] ,i th a sb e c o m ef e a s i b l et or e a da p p r o x i m a t e l y1 5 0
nucleotides from the 5 -end. Together, these enhancements
make it readily feasible to sequence RNA with approximately
300 nucleotides. In contrast to success in the sequence work
for small RNAs, two challenges remained. One challenge is
related to RNA size and the other is concerned with scarce
abundance of RNA in the cell. With the discovery of reverse
transcriptase,heatstableDNA polymerase,andrecombinant
technology, it became possible to produce cDNA, amplify,
and clone by RT-PCR methods.
With high-eﬃciency RT-PCR, high-molecular-weight
RNA with 10,000 nucleotides in length can be readily
sequenced [59]. A remaining shortcoming of this approach
is the inability to fully characterize modiﬁed nucleotides.
However, ability to deal with long chain lengths and scarce
abundance outweighs this limitation. cDNA-based methods
clearly dominate any RNA sequence work that involves long
RNA length or low RNA abundance. Examples are observed
in the direct gene isolation for cleavage controlled processing
RNAs (Pre-rRNA and rRNA) and cDNA method for pre-
mRNA and mRNAs. Therefore, as a result of accumulated
methodologies, it becomes common that RNA sequence
can be obtained through more than one scheme or type
o ft e c h n i q u e ,s u c ha ss t r a i g h tc h e m i c a la p p r o a c h e s[ 60]o r
biotechnology-mediated approaches.
4.3. Outlined Steps of Sequence Work. Brief outlines are
described for sequencing RNAs. It may be divided into two
methods although combined methodology is in fact feasible.
4.3.1. Direct Method of RNA Sequencing
(a) Preliminary Examination of External Glycol Structures. In
some cases, a rapid diagnostic examination is required. Most
convenient procedures employ the use of speciﬁc antibodies
against diﬀerent forms of 5 -cap structure (m7Gc a po r
m3
2,2,7G cap) and a oligo-dT column for poly-A aﬃnity
chromatography. Alternatively, a [3H]-derivative method
can be useful. The radioactive labeling of terminals was
performed using the periodate oxidation method, followed
byreductionwith[3H]-borohydride.T2 RNasedigestionand
fractionation by paper chromatography reveal the presence
of the 3 -terminal and 5 -cap.
(b)SelectionofLabelingMethods. RNAcanbelabeledinvivo
(prelabeling) or in vitro (postlabeling).
In vivo labeling is carried out by incubation of living
cells in the presence of [32P]-phosphate in a phosphate-free
medium. RNA is uniformly labeled by this method.
Invitrolabelingiscalledpostlabelingbecauseitlabelsthe
isolated RNA with isotopic agents such as [32P]-phosphate
or [3H]-borohydride. [32P]-labeling can be carried out using
kinase enzymes. The 5 -labeling is done with [32P]-ATP by8 Journal of Nucleic Acids
Table 6: General schemes of RNA sequencing. The direct and indirect methods of RNA sequencings are brieﬂy outlined. The cDNA and
DNA pathways are considered indirect methods.
Starting material RNA Starting material RNA
Endonuclease
Catalogs of oligonucleotides
Contig seeking
Large fragments
Endonucleases assisted sequencing
Ladder sequencing gel
Sequence
+
+
Modiﬁcations
RT-PCR
cDNA
library
Genomic DNA
library
Screening Screening
Clone Clone Clone
Restriction mapping
Shot gun
Subclone
Chain termination
Chemical degradation
Sequence
cDNA
amplify
polynucleotide kinase, that is, provided the 5 -end is free
from phosphate. If the 5 -end is blocked by the presence
of a 5 -cap structure, the pyrophosphate moiety must be
removed by a pyrophosphatase and phosphatase. And then
the kinase method can be employed to introduce the tracer.
Labeling at the 3 -end is done with [32P]-pCp by RNA
ligase. The [3H]-derivative (nucleotide diol) with [3H]-
borohydride indicates that the 3 -end is free from phosphate
or any other blocking structures. A shortcoming of [32P]-
labeling is the short half-life of the isotope which provides
a working period of approximately 4 half-lives. The main
limitation of the [3H]-labeling method is weak energy of
the tritium isotope. This can make the reading of the
autoradiograph for a ladder sequencing gel very diﬃcult.
(c) Initial Reading of Sequence by Ladder Sequencing Gel.
To obtain the nucleotide sequence of RNA quickly without
characterization of modiﬁed nucleotides, it is common
to use the endonucleases-dependent sequencing technique
[61]. Terminal labeled RNA (5 -end or 3 -end) is partially
digested with speciﬁc endonucleases (T1,U 2,A ,p h y sI ,a n d
others), and each product is loaded in parallel on a 10–15%
denaturingpolyacrylamidegel.Notethatifcrudeacrylamide
is used, the running temperatureof the gel canquicklyrise to
60–70◦C. Since the mode of cleavage is known, it is possible
to discern G (T1), A (U2), U and C (A) and C-resistance
(Phys I). It is not uncommon to read an RNA sequence using
this method within one day.
(d) Base Composition. There are two technical approaches
that can be used to determine RNA base composition (levels
of nucleotides or of nucleosides).
RNase T2 or alkali (0.3N KOH) is used to complete hy-
drolysis. But alkali (0.3N K/NaOH) is not preferred becauseJournal of Nucleic Acids 9
it destroys 7-methyl purines. Prelabeled [32P]-RNA is hydro-
lyzed, and its products are separated by 2-dimensional
paper chromatography followed by autoradiography [62].
Since the standard separation pattern is known, various
modiﬁed nucleotides are readily identiﬁed by comparison
[56].
Alternatively, after cold RNA is digested into constitu-ent
nucleotides, which are subsequently dephosphorylated by
phosphatase, the resulting nucleosides are converted into
[3H]-derivatives and separated by thin layer chromatogra-
phy. The separated nucleosides (including all modiﬁed nu-
cleosides except 2 -O-methylated nucleosides) are detected
byﬂuorographyandidentiﬁedbaseduponastandardmigra-
tion pattern (Figure 5)[ 9].
(e) Catalogs of Oligonucleotides. Two types of catalogs are
made. One is an RNase T1 catalog, and the other is an RNase
A catalog.
To map oligonucleotides, two necessary procedures are
essential. The ﬁrst is to prepare labeled oligonucleotides and
the second is to fractionate two-dimensionally.
To obtain labeled oligonucleotides, three approaches are
possible.
(1) Use of prelabeled [32P]-RNA for speciﬁc endonucle-
ase digestion.
(2) 5  labeling after enzyme digestion using [32P]ATP
and polynucleotide kinase.
(3) 3  labeling after endonuclease digestion and removal
of resultant 3 -phosphate by phosphatase. Then the
labeled derivatives can be formed by [32P]-5 -pCp
and RNA ligase or periodate oxidation followed by
[3H]-borohydride reduction.
To Map Oligonucleotides. There are a number of diﬀerent
techniques. However, the most common are a combination
of high voltage paper electrophoresis on cellulose acetate at
pH 3.5 and high voltage DEAE paper electrophoresis (7%
formic acid) or high voltage electrophoresis on cellulose
acetate at pH 3.5 followed by DEAE homochromatography
at 60–70◦C. Another method that can be used is two-
dimensional thin layer (PEI) chromatography using two-
solvent systems [63]. Detection is performed by autoradio-
graphy. It is notable that T1 oligonucleotides from 45S pre-
rRNA can be fractionated into approximately 200 spots by
homochromatography [64].
To Sequence Oligonucleotides. Several enzymatic digestions
can be exploited.
The recovered [32P]-oligonucleotides (prelabeled) are
subjected to secondary digestions with RNase U2 for place-
ment of A residues, RNase T1 for G residues, RNase A
for U, and C residues plus other endonucleases. Treatment
with exonucleases (spleen phosphodiesterase, snake venom
phosphodiesterase), and partial digestion with the enzymes
above is required to sequence RNA. In each step, nucleotide
composition is determined.
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Figure 5: Two-dimensional map of standard nucleosides [9]. The
[3H]-labeled standard nucleoside derivatives are separated by two-
dimensional thin layer chromatography. The ﬁrst dimension is
shown from bottom to top and the second dimension from left
to right. Solvent systems are in the text. N
  represents trialcohol
derivatives of representative nucleosides.
ToDeterminetheSequenceof 5 -Labeled[32P]-Oligo-Nucleot-
ides. A mobility shift test can be applied [56]. After partial
hydrolysis with snake venom phosphodiesterase the product
is fractionated by homochromatography or PEI thin layer
chromatography. The mobility shift pattern is produced
according to the step-wise loss of each nucleotide from
the 3 -end. The resulting pattern can be used to read the
sequence of the oligonucleotides.
To Determine the Sequence of [3H]-Oligonucleotides . The
procedures used for prelabeled [32P]-oligonucleotides are
applicable. Secondary digestion methods and accompanying
[3H]-derivative methods for the determination of nucleotide
composition can be carried out.
It may be necessary to strengthen the catalog of oligonu-
cleotides. Generally this involves the expansion of the catalog
to provide contiguous overlapping sequences. A feasible
approach is to produce large fragments (puriﬁed on 10–
15% denaturing polyacrylamide gel electrophoresis) and
identify the overlapping oligonucleotides. Usually a limited
fragmentation by a diluted endonuclease at low temperature
orwaterhydrolysismayproducelargeoverlappingfragments
[63]. Examination of large fragments, as done above for
ladder gel sequencing and catalogs, can often clarify any
ambiguity encountered. An excellent example of one hit
hydrolysis is observed in the work on tRNA structure [63].
Based on these very same methods, it can be summarized
that many small RNAs have been sequenced. These include
tRNAs, pre-tRNAs, 4.5S RNA I, 5S rRNA, 5.8S rRNA,
snRNAs, snoRNAs, 7S RNA, and some fragments of pre-
rRNA, 28S rRNA, and 18S rRNA.10 Journal of Nucleic Acids
4.3.2. Indirect Method of RNA Sequencing. The indirect
method of RNA sequencing using cDNA or DNA gene
analysis was developed as part of explosive advancements
with DNA biotechnology. The direct RNA sequencing
method proved useful for the characterization of small
RNAs (∼100–300nt). However, sequencing high-molecular-
weight (HMW) RNAs proved to be too diﬃcult. Moreover,
HMW RNAs that are scarce abundance often do not meet
the sample amounts required by the former methods. The
search for a solution to this dilemma was successful. One
solution involved the isolation of the gene that codes for
a speciﬁc RNA and the other is to synthesize cDNA which
can also be used to isolate a speciﬁc RNA gene. Using
DNA biotechnology, it proved possible to scale up and
solve “The Human Genome Project.” Several genomes have
been sequenced, speciﬁcally the human (2.9Gb) and mouse
(2.5Gb) genomes [65–67]. In well equipped laboratories, it
is possible to sequence DNA at the rate of 106–107 nt/day.
This technology has been widely commercialized and is
currently available as kits for cDNA cloning, sequencing,
along with enzymes and equipment that supports automatic
sequencing.The principal objective ofthe genomic approach
was to determine the sequences of the coding genes. Vast
collections of sequence data were compiled for RNAs,
cDNAs,andgenomicstructures,revealingthebasesequences
for a number of RNAs. As a result of this work.
(a) Unidentiﬁed proteins have been predicted to number
25,243;whereastheknownproteinnumberis15,337.
(b) A majority of mRNA species (95%) mature through
alternative splicing mechanisms.
(c) Disease genes are estimated to be 2,577 in number.
(d) Point mutations are 31,250 in number; half of
disease-causing mutations are attributed to aberrant
splicing (disruption of splicing codes) whereas other
forms of mutation include disruption of the genetic
code.
(e) Disruption of splicing code occurs at the splice site
and enhancer/silencer sites of exonic and intronic
sequences.
(f) Pathogenic sequences that occur as a result of splice
code mutations (transition and transversion) cause
aberrant modiﬁcations of a variety of RNAs [68, 69].
Recently, evidence has been accumulating that suggests
a need to revise earlier estimates of the number of tran-
scriptional products arising from the genomic information.
Paradoxical ﬁndings were obtained that contradicted earlier
and more conservative estimates of the proteasomes size
(50,000), in fact, the cellular transcripts are 2-3 times higher
than estimated earlier [50, 51]. Also, 50% of the transcripts
were comprised of noncoding RNA, some of which are
polyadenylated. This paradoxical manifestation has led to
the second generation of genomic work, strictly based on
RNA characterization. It is worth emphasizing that this has
become the second genomic frontier where a reevaluation of
the ﬁrst genomic work is necessary. The present task is more
daunting than the “The ﬁrst Generation Genome Project.”
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Figure 6: Stereochemistry of the reaction catalyzed by RNase A
[10]. The intermediary 2 ,3  cyclic nucleotide (cNp or cNMP) is
hydrolyzed to a 3  phosphorylated mononucleotide. Other 2 -OH
requiring enzymatic and alkaline hydrolysis may go through the
same path.
The task at hand is to resequence the genome and then
categorize and catalogue the ncRNA species by utilizing all
available sequence means, including direct sequencing and
DNA microarray techniques.
The next step is to construct secondary structures accor-
ding to enzyme susceptibility and computer-aided base pair-
ing. Interacting proteins will need to be deﬁned by biochem-
ical, NMR, X-ray, and cryo-EM methods.
5.Reagent andProceduresRequired
for Sequencing
5.1. RNA-Speciﬁc Cleavage Reactions (2 -OH Required
Reaction)
(1) Mild alkaline hydrolysis (0.3N KOH) produces 3 
monophosphorylated nucleotides.
(2) T1 RNase cleaves phosphodiester bonds after G base
producing 3  GMP at the 3  ends.
(3) RNase A cleaves phosphodiester bonds after pyrim-
idines (U and C) producing 3  phosphates at 3  ends.
(4) T2 RNase cleaves all phosphodiester bonds with a
preference for A residues, producing 3  monophos-
phates.
(5) U2 RNase cleaves phosphodiester bonds after A base,
producing 3  monophosphates.
The mechanism catalyzed by alkaline hydrolysis, RNase
A, T1 RNase, T2 RNase and U2 RNase involves a SN2(p)
mechanism attacking 2 -hydroxyl groups on the adjacent
internucleotidic phosphodiester bond to displace the 5 -
hydroxyl group of the neighboring nucleotides and generate
a2  ,3  -cyclic nucleotide intermediate. A subsequent hydrol-
ysis of the 2 ,3  -cyclic nucleotide yields a ﬁnal product, a 3 
mononucleotide (Figure 6).Journal of Nucleic Acids 11
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Figure 7: The CMCT reaction of pseudouridine (Ψ) and uridine, and the structure of CMCT [11] .A d d u c t sf o r m e dw i t hC M C To nΨ and
U are shown. This adduct formation prevents the cleavage by RNase A at U but not at C. The mild alkaline treatment of reaction products
destroys the U but not the Ψ. These diﬀerences were utilized to locate the position of Ψ by reverse transcriptase.
5.2. The Enzymes Cleaving All Phosphodiester Bonds Including
2 -O-Methylated Ribose
(1) P1 RNase: the enzymatic digestion by P1 RNase
cleaves all phosphodiester bonds (except pyrophos-
phate linkages), producing 5  monophosphorylated
nucleotides.
(2) The enzymes acting from the ends for sequencing
fragments
(a) Snake venom phosphodiesterase (phosphodi-
esterase I) cleaves phosphodiester bonds, as
well as pyrophosphate bonds producing 5 
monophosphorylated nucleotides. It cleaves
single-stranded RNA or DNA from the 3  end
in a progressive manner.
(b) Spleen phosphodiesterase (phosphodiesterase
II) produces 3  monophosphorylated nucleo-
tides cleaving from nonphosphorylated 5  ends
of single-stranded RNA or DNA.12 Journal of Nucleic Acids
5.3. Other Enzymes Utilized for Sequencing
(1) Alkalinephosphataseremovesphosphatefrom3  and
5  ribose moieties.
(2) Pyrophosphatase will only cleave pyrophosphate
linkages. There are pyrophosphatases from tobacco
and potato as well as from Crotalus adamanteus
venom type II.
Using varying combinations of fragmentation meth-
ods, it becomes possible to obtain fragments that
range in size from nucleosides to very large frag-
ments.
5.4. Chemical Modiﬁcations Used for Sequencing
5.4.1. CMCT Reaction. Originally reported by Gilham [73],
the adduct formation of uridine and guanosine components
of RNA with CMCT made uridine residues resistant to
RNase A. In addition it has been shown that CMCT reacts
with pseudouridine and to a lesser extent with inosine. This
reactiontakesplaceonΨ(N1,N3),U(N3),G(N1),andI(N1),
and cold dilute ammonia removes the adducts from Ψ(N1)
and hot concentrated ammonia removes remaining adducts
from Ψ(N3) [74, 75] .T h e s ep r o p e r t i e sh a v eb e e nu s e dt o
block RNase A digestion at U but not at C as well as to
diﬀerentiate U from Ψ (Figure 7)[ 11].
DirectchemicalmethodsforsequencingRNAusingdim-
ethyl sulfate, diethyl pyrocarbonate, and hydrazine followed
by aniline-β-elimination have been successfully utilized in 5S
R N Aa n d5 . 8 SR N As e q u e n c ea n a l y s i s[ 60].
5.4.2. DMS (Dimethylsulfate). This has been used to identify
secondary structures as well as for the synthesis of standard
m3
2,2,7G. The properties of DMS modifying adenosine (N1)
and cytosine (N3) make modiﬁed nucleotides unable to
base-pair. For this reason RT-PCR stops one nucleotide
before the modiﬁed nucleotide enabling the location
of a modiﬁed nucleotide as well as diﬀerentiating the
single-stranded from double-stranded regions of RNA.
DMS also has been used for synthesis of m3
2,2,7Gf r o m
N2,N2-dimethylguanosine. For this synthesis, the reaction
has been carried out by the methods of Saponara and
Enger [76]. Twenty milligrams of N2,N2-dimethylguanosine
were suspended in 400μL of dimethylacetamide containing
10μL dimethylsulfate. The mixture was shaken for 15
hours at room temperature and then centrifuged to remove
insoluble products. The supernatant was adjusted to pH
8.0 with concentrated ammonia and then placed on a
phosphocellulose column (1 × 50cm) at pH 7.0 (0.001M
ammonium acetate). A linear gradient of 0.001–0.3M
ammonium acetate was used to elute the samples. One
major peak of the product (m3
2,2,7 trimethylguanosine)
was found between two minor peaks (corresponding to
N2,N2-dimethylguanosine and 7-methylguanosine). The
product was lyophilized and identiﬁed as m3
2,2,7Gb ym a s s
spectrometry [12]. The summary of reagent and procedures
required for sequencing is provided in Table 7.
Thenucleotidesornucleosidesobtainedcanbeseparated
by column chromatography, paper electrophoresis or thin
layer chromatography to determine the number of G, A.
U, C and modiﬁed residues in the fragments or in the
molecule. These 4 bases have speciﬁc UV spectra and
chemical reactivity to identify the nature of the bases in
comparison with known standards. The unusual nucleo-
side, trimethylguanosine, has its speciﬁc UV absorption
spectra (Figure 8) and mass spectrometric characteristics
(Figure 9).
6. The Major snRNA Sequenced
The ﬁrst nuclear small RNA sequenced was 4.5S RNAI [77]
shown in Figure 37. This RNA contains the RNA polymerase
III promoter box A and box B like motifs and shows
interesting enhancer motif elements resembling the Alu
element transcript. The RNA polymerase III promoter areas
are underlined and the ﬁrst nucleotide of the enhancer motif
is marked by colored letters. The red color is SF2/ASF (4
motifs),bluecolorisSC35(3motifs),greencolorisSRp40(6
motifs), and yellow color is SRp55 (1 motif) (Figure 10(a)).
It also exhibits 3 -splice sites marked by [AG] as well as
branch sites with the highest score marked by {CACCUAU}
(Figure 10(b)). The ESE (exonic splice enhancer), splice sites
(Figure 10(c)), and branch sites were examined by ESEﬁnder
3.0 [13].
In comparison with known Alu elements in the FMR1
gene, the resemblance of 4.5S RNA I in ESE, 5 SS, BS,
and 3 SS distribution (Table 8) suggests that 4.5S RNA I is
more likely derived from an Alu gene expressed in Novikoﬀ
hepatoma cells.
The Alu element has been shown to have many diﬀerent
functions in transcription, splicing, exonization [78],
gene insertions (transposons), and DNA replication. It is
interesting to observe that the (+) oriented Alu has more
5  splice sites and the (−)o r i e n t e dA l uh a sm o r e3   splice
sites. It may suggest that exonization may occur from the
5  side of (+) Alu elements and 3  side of (−) Alu elements.
T h eS R PR N A( 7 S LR N A )h a sA l ue l e m e n t si ni t ss e q u e n c e
[79]. Whether the Alu is derived from 7SL or Alu is exonized
to 7SL is not clear. Subsequently, other snRNAs have been
sequenced.
The sequences of the capped snRNAs are described in
Figure 11. The pivotal sequences needed for functions are
marked by colors.
In the course of any sequence work, there are always
challenges in resolving unknown structures at the 5  end
portions which contain the 5 -cap structure and various
modiﬁed nucleotides. The experimental steps required to
discern this complicated region are described.
7. Nucleotide Composition and Modiﬁed
Nucleotides in snRNAs
The compositional analyses were carried out by UV analysis
as well as isotope labeling analysis. For example, UV analysis
required ∼10mg of U2 RNA.Journal of Nucleic Acids 13
Table 7: Reagents and procedures required for sequencing.
Detection of external
modiﬁcation
Oligo-dT column
Borate column
Antibodies against m7G, m3
2,2,7G, and
others
Labeling
Prelabeling (in vivo) with
[32P]-phosphate
Postlabeling (in vitro)
5  [32P] labeling
3  [32P] labeling
3  and 5  [3H]-derivative labeling
Enzymes
Endonucleases
RNase T1(Gp↓N), RNase A(Up↓No r
Cp↓N), RNase U2(Ap↓N),
PhysI(C-resistance), RNase T2(Np↓N),
RNase P1(pNm↓pN, pN↓pN),
Debranching enzyme N
2-↓5pNp
3-p Np -
Exonuclease
Spleen phosphodiesterase (Np↓Np↓Np)
−→
Snake venom phosphodiesterase
− →
(N↓pN↓pNp and N5p↓p↓p5N)
−→ − →
Pyrophosphatase (-p↓p-)
Phosphatase Phosphatase (p↓N and N↓p)
Chemicals
CMCT React with U>Ψ>G>I on ssRNA
DMS Methylate G>A>C on ssRNA
Diethyl
pyrocarbonate React with A>G
Hydrazine React with U>>C>T
Limited hydrolysis Formamide
Hot water (80◦C)
Fractionation
2D acrylamide gel electrophoresis
2D homochromatography
2D electrophoresis
2D paper chromatography
2D thin layer chromatography
7.1. RNA Terminal Labeling with [3H]-KBH4. The puriﬁed
nuclear RNAs were separated by sucrose gradient centrifu-
gation which separates 4–8S RNA, 18S RNA, 28S RNA,
35S RNA, and 45S RNA isolated from nuclei of rat liver,
Walker tumor, or Novikoﬀ hepatoma cells. As an initial step
for the structural characterization, 3  end nucleosides were
labeled by the procedure of sodium periodate (NaIO4)o x i -
dation and potassium borohydride ([3H]-KBH4)r e d u c t i o n .
The reaction was carried out in 0.1M sodium acetate buﬀer
at pH 5 with freshly prepared NaIO4 in the dark for 1
hour and precipitated the RNA with ethanol. The RNA was
redissolved in the same buﬀer and treated with ethylene
glycol to destroy excess NaIO4. The RNA was precipitated
with ethanol and redissolved in 0.1M sodium phosphate
buﬀer, pH 7.7, and treated with radioactive [3H]-KBH4 [38].
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Figure 8: The UV spectra of pm3
2,2,7G[ 12]. The ultraviolet absorp-
tion spectra were recorded on a Cary 14 spectrometer immediately
after addition of compound to solutions at pH 2, 7, and 12.
These reaction products would have tritium labeling in cis-
alcohols from cis-aldehyde oxidation products of the 2  and
3  hydroxyls of ribose, assuming all 3  ends of RNA have
accessible 2  and 3  OH groups (Figure 12).
The labeled 4–8S RNAs were separated by preparative
polyacrylamide gel electrophoresis (Figure 13) and DEAE-
Sephadex column chromatography (Figure 14)t op u r i f y
individual snRNAs (U1, U2, U3, 4.5S RNA I, II, and III, 5S
RNA I, II, and III).
Alkaline hydrolysis of these RNAs produced 3  end
nucleoside trialcohol derivatives (Table 9)w h i c hw e r es u b -
sequently identiﬁed by paper chromatography.
T h eR N At h a ta p p e a r e dt ob ep u r ef o rs e q u e n c i n gw a s
4.5S RNA I which had 87.4% U at the 3  terminus and only
6.5%unknownradioactivityattheorigin.Unexpectedly,U1,
U2, U3, 4.5S RNA II, and some of 5S RNA (5S RNA III/U5)
had ∼50% labeling in alkaline-resistant fragments that did
not move as nucleoside derivatives. The 4.5S RNA III was
not labeled by this procedure suggesting a blocked 3  end
(Figure 14). The U1, U2, and U3 RNAs were labeled with
tritium, digested with RNase A, and separated on a DEAE-
Sephadex column (Figure 15).
The oligonucleotides were digested with T1 RNase and
rechromatographed, and only the U3 oligonucleotide was
shortened by one nucleotide, indicating the presence of one
G adjacent to RNase A susceptible pyrimidine [80]. In the
course of sequencing U1, U2, U3 RNAs, it was found that
the oligonucleotides with m3
2,2,7G was coming from the
5  end segments. The only way 2 3  hydroxyls could be at14 Journal of Nucleic Acids
500 450 400 350 300 250 200 150 100 50
281
%
∑
4
3
%
∑
4
3
21.5
15
10
5 629
100
75
50
25
103
73
73
147 217 252
281
614
629
O−
CH3
N+
N
N
N (CH3)2N
N
O
N
N
N
(CH3)2N
CH3
HOCH2
O
HO OH
OSi(CH3)3
CF3C = NSi (CH3)3
(CH3)3 SiO
(CH3)3 SiO
OSi (CH3)3
(CH3)3 SiOCH2
O
Unknown nucleoside from hepatoma Novikoﬀ
50 5
100
100
200 300 400 500 600
600
(m/g)
(m/g)
R
e
l
a
t
i
v
e
i
n
t
e
n
s
i
t
y
R
e
l
a
t
i
v
e
i
n
t
e
n
s
i
t
y
Synthetic 2, 2, 7-trimethylguanosine
280
Trimethylsilylation of N2,N 2,7
trimethylguanosine
2 1
23
-
Figure 9: The mass spectra of trimethylguanosine [12]. The synthetic m3
2,2,7G and unknown nucleoside from U2 RNA were trimethyl-
silylated and subjected to LKB 9000 gas chromatograph-mass spectrometer. The mass spectrum of the unknown nucleoside from U2 RNA
was identical to synthetic m3
2,2,7G.
Table 8: Distribution of ESE, 5  splice sites, branch sites, and 3  splice sites. The ESE, 5  splice site, branch site, and 3  splice site in 4.5S
RNA I and Alu elements in FMR1 gene transcript are screened by ESE ﬁnder (version 3) [13]. For this comparison, the number of motifs is
calculated per 100 nucleotides. The motif patterns in Alu elements are all very much alike and the 4.5S RNA I resembles them. A diﬀerence
is found in that 5  splice sites in (+) Alu are more than in (−)A l ua n d3   splice sits are more in (−) Alu than in (+) Alu.
SF2/ASF SC35 SRp40 SRp55 Total 5 SS BS 3 SS
Novikoﬀ 4.5S RNA I (96nt) 3.65 3.13 6.25 1.04 14.07 0 10.4 2.08
Human FMR1 Alu1(+) (252nt) 4.96 7.54 6.35 1.59 20.44 3.97 9.13 5.56
Human FMR1 Alu4(+) (295nt) 4.41 4.41 1.69 2.03 12.54 2.37 10.9 2.37
Human FMR1 Alu5(+) (246nt) 5.69 5.28 4.47 1.22 16.66 4.47 8.54 2.44
Human FMR1 Alu7(+) (290nt) 6.21 2.41 3.10 0.34 12.06 3.79 10.3 2.07
Human FRM1 Alu8(+) (288nt) 5.21 3.47 3.82 0.69 13.19 3.47 8.68 2.43
(+) Alu Av. 5.30 4.62 3.89 1.17 14.98 3.61 9.51 2.97
Human FMR1 Alu2(−) (298nt) 3.69 6.04 5.03 1.34 16.10 0.67 14.1 4.70
Human FMR1 Alu3(−) (285nt) 4.92 7.02 5.61 2.11 19.66 3.16 13.7 4.56
Human FMR1 Alu6(−) (290nt) 4.31 5.52 4.48 1.38 15.69 2.76 13.5 4.48
(−) Alu Av. 4.31 6.19 5.04 1.61 17.15 2.20 13.8 4.58
Human FMR1 Total Alu(+&−) Av. 4.93 5.21 4.32 1.34 15.80 3.08 11.1 3.58
5  end was 5 -5  pyrophosphate linkage to the rest of the
RNA molecules [36]. The RNase A and T1RNase resistant
oligonucleotides were digested with various enzyme combi-
nations including snake venom phosphodiesterase, alkaline
phosphatase, P1 RNase, T2 RNase, and U2 RNase into
nucleosides. The component nucleosides were identiﬁed by
mass spectrometry, U.V. spectroscopy, HPLC (high pressure
liquid chromatography), paper chromatography, and thin
layer chromatography. [12, 16, 37, 58].
7.2. Tritium Labeling of Nucleosides. The puriﬁed RNAs were
digested with RNase A, snake venom phosphodiesterase,
and alkaline phosphatase at pH 8.0, 37◦Cf o r6h o u r s
into nucleosides. The digest was treated with a 2X molarJournal of Nucleic Acids 15
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Figure 10: ESE motifs in 4.5S RNA. The sequences of 4.5S RNA
I from Novikoﬀ hepatoma cell nuclei were screened by ESE ﬁnder
3[ 13] for ESE, 5  splice sites, branch sites, and 3  splice sites. The
default threshold value was used. There were 4 SF2/ASF sites, 3
SC35 sites, 6 SRp40 sites, 1 SRp55 sites, 10 branch sites, and 2 3 
splice sites. These numbers resemble the number identiﬁed in Alu
elements of human FMR1 transcript (Table 8).
Table 9:ThesnRNA2  and3 -OHlabelingbyNaIO4 oxidationand
[3H]-KBH4 reduction [38]. The total 4–7S RNA from rat Novikoﬀ
hepatoma cell nuclei was labeled with [3H] by oxidation with
NaIO4 followed by [3H]-KBH4 reduction (Figure 12). Individual
RNA species were puriﬁed by gel electrophoresis (Figure 13). The
RNA samples were hydrolyzed with 0.3N KOH, and hydrolysates
were chromatographed on whatman 3MM paper according to de
Wachter and Fiers [55]. The radioactivities at the origin (22%
for 5S RNA, 54.1% for U1 RNA, 49.7% for U2 RNA, and 50.6%
for U3 RNA) represent % of total radioactivity applied and they
represent the 5  end labeling which was later elucidated by many
enzymatic methods described in the text. The radioactivities moved
by chromatography with standard nucleoside derivatives are the
% of total in nucleosides derivatives. The A  U  G  C  represent
trialcohol derivatives of nucleosides.
3  Nucleoside derivatives
RNA Species Radioactivity
at origin (5 ) A  U  G  C 
%% % % %
4S RNA 10.9 89.0 3.2 3.9 3.8
4.5S RNA 15.8 11.2 79.7 4.0 5.1
4.5S RNA I 6.5 6.1 87.4 4.7 1.8
4.5S RNA II 30.9 13.1 80.2 4.7 2.4
5S RNA 22.0 11.4 75.5 6.0 7.0
U1 RNA 54.1 6.0 13.4 77.7 3.0
U2 RNA 49.7 61.5 6.0 4.3 28.2
U3 RNA 50.6 53.8 22.6 9.8 13.7
excess of NaIO4 and labeled with [3H]-KBH4 at pH 6
for 2 hours in the dark to produce trialcohol derivatives
of nucleosides. All nucleosides with base modiﬁcations,
except 2 -O-ribose modiﬁed, were labeled with tritium. The
tritium-labeled trialcohol derivatives were separated by two-
dimensional TLC (thin layer chromatography) on cellulose
thinlayers(Figure 5)[81].Theﬁrstdimensionusedasolvent
of acetonitrile, ethylacetate, n-butanol, isopropanol, 6N
aqueous ammonia (7:2:1:1:2.7); the second dimension
used a solvent of tert-amyl alcohol, methylethylketone,
acetonitrile, ethylacetate, water, formic acid (sp.gr. 1.2)
(4:2:1.5:2:1.5:0.18)[81, 82].
7.3. [32P] Labeling of RNA. The Novikoﬀ hepatoma cells
were transplanted intraperitoneally into male albino rats
of the Holtzman strain weighing 200–250g, obtained from
Cheek Jones Company (Houston, Tex). After 5-6 days, the
cells were harvested and washed with NKM solution (0.13M
NaCl, 0.005M KCl, and 0.008M MgCl2). Twenty milliliter
(packed volume) of cells was incubated with 500mCi of
[32P]-orthophosphate in 1 liter of medium (phosphate free
modiﬁed Eagle’s minimal essential medium) for 9–16 hours
[83]. Nuclear RNA was puriﬁed by sucrose gradient cen-
trifugation,gelelectrophoresis,andcolumnchromatography
[38].ThepuriﬁedRNAwashydrolyzedwith0.3NKOH,and
alkaline-resistant oligonucleotides were separated on DEAE-
Sephadex.Thealkalineresistantdinucleotideswerecollected,
treated with alkaline phosphatase, and identiﬁed by two-
dimensional chromatography (Figure 16).16 Journal of Nucleic Acids
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Figure 11: Sequences of major snRNAs (see [15–30]). The sequences of major snRNAs from human and rat involved in splicing and
processing are aligned for comparison. The sequence elements in major spliceosomal snRNAs and processosomal snoRNAs are highlighted
in the sequences. Those are the pivotal motifs for the function. The numbers in parenthesis are the chain length of the RNAs.
The summary of modiﬁed nucleotides is in Table 1 [84]. 8.StructuralDeterminationof
5  Oligonucleotides
The structures of the 5  ends of U1 RNA, U2 RNA, U3
RNA, and 5S RNA III (U5) are determined by the charac-
teristics of chemical reactions and enzymatic susceptibilities
(Figure 17).18 Journal of Nucleic Acids
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Figure 12: RNA 5  and 3  end labeling with [3H] by treatment with NaIO4 and [3H]-KBH4. The 4–7S RNA from Novikoﬀ hepatoma cell
nuclei was labeled to detect the presence of free 2 -OH and 3 -OH by NaIO4 oxidation followed by [3H]-KBH4reduction. The reaction
occurred at both ends of RNA (5  end and 3  end).
8.1. U1 RNA 5  End Oligonucleotide. The U1 RNA labeled
with [3H] by NaIO4 and [3H]-KBH4, digested with RNase
A, showed enzyme-resistant oligonucleotide eluting close to
the pentanucleotide region on a DEAE column (Figure 15).
The 5  oligonucleotide was analyzed by UV, [3H], and [32P]
methods.
8.1.1. The UV Analysis. The 5  oligonucleotides from U1
RNA,obtainedbyRNaseAandRNaseT1,weredigestedwith
snake venom phosphodiesterase and alkaline phosphatase.
The nucleosides produced were separated on HPLC (high
pressure liquid chromatography) [strongly basic cation
exchange (quaternary amine)]. As shown in Figure 18, the
amount of nucleoside ratio was 1.0, 1.2, 1.2, 0.7, and 0.9
for Am, A, Um, m3
2,2,7G, and C, respectively, for U1 5 
oligonucleotide.
8.1.2. The [3H] Method. The [3H]-labeled U1 RNA 5  oligo-
nucleotide, following digestion with snake venom phos-
phodiesterase and alkaline phosphatase, was separated byJournal of Nucleic Acids 19
0.2
0.1
50 100 150
Fraction number
C
o
u
n
t
s
p
e
r
m
i
n
u
t
e
p
e
r
5
0
μ
L
6000
5000
4000
3000
2000
1000
4S
5S
4.5S
U1
U2
U3
A
b
s
o
r
b
a
n
c
e
a
t
2
6
0
n
m
Radioactivity
Absorbance
Figure 13: Preparative gel electrophoretic pattern of 4–7S RNA
labeled with [3H] [16]. The intact, labeled RNA (as in Figure 12)
was subjected to preparative polyacrylamide gel electrophoresis.
The UV absorption and radioactivity were measured.
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Figure 14: DEAE-Sephadex column chromatography of 4.5S
RNA [38]. The 4.5S RNA from preparative gel electrophoresis
was collected and chromatographed on a DEAE-Sephadex A-50
column. It was separated into 3 peaks but no radioactivity in 4.5S
RNA III was detected, indicating the absence of accessible 2 -OH
and 3 -OH in this molecule. The 4.5S RNA II may be the U6 RNA.
chromatographic methods with standards. Two-dimensional
TLC (thin layer chromatography) and paper chromatog-
raphy demonstrated that the [3H] labeled compound is a
trimethylguanosine derivative (Figure 19).
8.1.3. 32P-Labeled 5  Oligonucleotide from U1 RNA. The 32P-
labeled RNA was digested with T2 and U2 RNase, and
digestion products were separated by two-dimensional elec-
trophoresis. The ﬁrst dimension was on cellogel at pH 3.5,
and the second dimension was on DEAE paper at pH 3.5
(Figure 20).
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Figure 15: DEAE-Sephadex chromatography of 5  oligonucleotide
[37]. The U1 RNA, U2 RNA, and U3 RNA collected from prepar-
ative gel electrophoresis (Figure 13) were digested with RNase A
and subjected to DEAE-Sephadex A-25 column chromatography.
The radioactive peaks at nucleoside region were coming from 3 
ends and the radioactivities at the regions of penta-, tetra-, and
hexanucleotides were from 5  end labeling. These fragments were
treated with T1 RNase and found to be shortened by one nucleotide
only in U3 5  oligonucleotide indicating that G was next to the
terminal pyrimidine nucleotide.
Spot“a”waselutedandtreatedwithalkalinephosphatase
and chromatographed with GMP, GDP, and GTP standards.
The 32P-labeled 5  oligonucleotide was chromatographed in
the GTP region on a DEAE-Sephadex column (Figure 21).
The oligonucleotide peak from the GTP region was
digested with snake venom phosphodiesterase and separated20 Journal of Nucleic Acids
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Figure 16: Two-dimensional separation of alkali stable dinucleo-
side monophosphate [18, 39]. (a) Standard dinucleoside mono-
phosphates (NmpN) were separated on Whatman no.1 paper with
the solvent systems ethylacetate-1-propanol-water (4:1:2, v/v) in
the ﬁrst dimension and in the second dimension with 2-propanol-
water-concentrated ammonium hydroxide (7:2:1, V/V). (b) Auto-
radiograph of two-dimensional separation of alkali-stable dinucle-
oside monophosphate of U2 RNA from Novikoﬀ hepatoma cell
nuclei. The [32P]-labeled U2 RNA was hydrolyzed by 0.3N NaOH,
and the sample was separated on a DEAE-Sephadex column A-25 at
pH 7.6. The dinucleotides were collected and treated with alkaline
phosphatase. The alkali stable dinucleoside monophosphates were
separated on Whatman no. 1 paper and autoradiographed with X-
ray ﬁlm.
by electrophoresis in the ﬁrst dimension followed by chro-
matography on second dimension (Figure 22).
The 32P activity ratio was 1.00, 1.11, 1.25, 0.53, and
1.14 for pm3
2,2,7G, pAm, pUm, pA, and Pi, respectively. The
peak from the GTP region in Figure 21 digested with RNase
P1 produced pUm, pA (peak a in Figure 23), and cap core
m3
2,2,7GpppAm (peak b in Figure 23). Table 10 shows the
radioactivity distribution in peaks a and b in Figure 23.
For the analysis of a number of phosphates in cap core
(peak b), the cap core was treated with NaIO4 and aniline to
remove m3
2,2,7Gb yβ-elimination reaction (Figure 24).
The product was chromatographed on a DEAE column
with standard AMP, ADP, and ATP. The product was
eluted close to ATP, indicating that it is pppAm. This
experiment proved that the 5  oligonucleotide structure is
m3
2,2,7GpppAmpUmpApCp.
8.2. U2 RNA 5  End Oligonucleotide. The U2 RNA labeled
with NaIO4 and [3H]-KBH4 was digested with RNase A. The
labeled oligonucleotide eluted around the tetranucleotide
region (Figure 15). The 5  oligonucleotide was analyzed by
UV, [3H], and [32P] methods.
8.2.1. UV Analysis. The 5  oligonucleotide obtained by com-
plete RNase A digestion was analyzed for its base composi-
tion. The puriﬁed 5  oligonucleotide was digested with snake
venom phosphodiesterase followed by alkaline phosphatase.
The digestion product (nucleosides) was separated by HPLC.
The composition was Am, Um, C, and m3
2,2,7Gi nar a t i oo f
1.0, 1.3, 1.1, and 0.96, respectively, (Figure 18)[ 12]. These
nucleosides were also separated by two-dimensional TLC in
a borate system. Um and Am migrated through the butanol-
boric acid while the m3
2,2,7G and C, which form complexes
with borate, were retarded in the butanol-boric acid phase
(Figure 25).
The UV spectra of pm3
2,2,7G were typical of a trimethyl
Gn u c l e o t i d e( Figure 8) .T h em a s ss p e c t r o m e t r yo ft h e
unknown nucleoside from U2 RNA 5  fragment was iden-
tiﬁed as m3
2,2,7 trimethylguanosine (Figure 9).
8.2.2. [3H]-Labeled U2 RNA 5  Oligonucleotide. The puriﬁed
U2 RNA, labeled with NaIO4 and [3H]-KBH4 methods, was
digested with RNase A and 5  oligonucleotide puriﬁed by
DEAE-Sephadex column chromatography (Figure 15). The
puriﬁed 5  oligonucleotide was digested with snake venom
phosphodiesterase followed by alkaline phosphatase. The
nucleosides obtained were separated on two-dimensional
TLC [12] and 3MM paper chromatography. The tritium-
labeled compound was identiﬁed as a trialcohol derivative of
m3
2,2,7G( Figure 26).
8.2.3. [32P]-Labeled U2 RNA 5  Oligonucleotide. The [32P]-
labeled U2 RNA was digested with T1 RNase or RNase A.
Half of each 5  oligonucleotide was digested with alkaline
phosphatase. Oligonucleotides were subsequently digested
with snake venom phosphodiesterase, and the resulting
5  nucleotides were separated ﬁrst by electrophoresis and
second by chromatography (Figure 27). The ratio of [32P]
counts is shown in Table 11.
The U2 RNA 5  oligonucleotide obtained by RNase A
was subjected to digestion with pyrophosphatase (Crotalus
adamanteus venom type II, Sigma). The remaining oligonu-
cleotide did not have m3
2,2,7G, indicating that the m3
2,2,7Gi s
linked by pyrophosphate linkage (Figure 28).Journal of Nucleic Acids 21
Trimethyl guanosine caps of Novikoﬀ hepatoma cell snRNAs
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Figure 17: Characterization of m3
2,2,7G caps of snRNAs U1, U2, U3, and U5. The enzyme susceptible bonds are indicated with arrows. The
split arrows indicate that some bonds without 2 -O-methylation can be cleaved but the ones with 2 -O-methylated ribose are not.
Table 10: The [32P]cpm radioactivity distribution in nucleotides
and cap core produced by RNase P1 digestion of U1 5  oligonu-
cleotide [16]. The [32P]-labeled U1 5  oligonucleotide obtained by
digestion of U1 RNA with RNase T2, RNase U2, and alkaline phos-
phatase was treated with P1 nuclease which cleaves all phosphodi-
ester bonds but not pyrophosphate bonds. The products were sep-
arated on a DEAE column (Figure 23). The radioactivity in peak a
(mononucleotides pUm, pA) and peak b (cap core m3
2,2,7GpppAm)
were determined by Packard liquid scintillation spectrometer.
Peak a (pUm, pA) Peak b (m3
2,2,7GpppAm)
U1 5  cap 65,280 87,600
Fromthesedatathe5  endoligonucleotidefromU2RNA
has been deduced to be m3
2,2,7GpppAmpUmpCpGp.
8.3. U3 RNA 5  End Oligonucleotide. The [3H]-labeled U3
RNA was digested with RNase A and or T1 RNase. The [3H]-
labeled 5  oligonucleotide obtained by RNase A digestion
was eluted in the hexanucleotide region (Figure 15). The
[32P]-labeled U3 RNA digested with T2 and U2 RNA
produced 2 spots that were separated by two-dimensional
electrophoresis (Figure 29).
8.3.1.UVAnalysis. The5  oligonucleotide obtained fromU3
RNA by digestion with RNase A and T1 RNase was isolated
by column chromatography. The puriﬁed 5  oligonucleotide
was digested with snake venom phosphodiesterase and alka-
linephosphatase.Thenucleosidesobtainedweresubjectedto
HPLC. The molar ratios of m3
2,2,7G ,A m ,A ,a n dGw e r e1 . 0 ,
1.7, 1.1, and 1.0, respectively (Figure 18).
8.3.2. [3H] Analysis. The intact U3 RNA, labeled with NaIO4
and [3H]-KBH4 methods, was digested with RNase A and
chromatographed on DEAE-Sephadex (Figure 15). Subse-
quent digestion by T1 RNase released only one nucleotide
from the RNase A oligonucleotide, indicating that the G was
adjacent to a RNase A susceptible pyrimidine. The puriﬁed
5  oligonucleotide obtained after T1 RNase and RNase A
was digested with snake venom phosphodiesterase followed
by alkaline phosphatase. The nucleosides and trialcohol
derivativeswereseparatedbyTLC(Figure 30).Thetrialcohol
derivativeofm3
2,2,7Gindicatesthatthisnucleotidehasfree2 
and 3  OH at the end of the intact molecule.
8.3.3. [32P] Analysis. The [32P]-labeled U3 RNA digested by
T1 RNase and U2 RNase was separated by two-dimensional
electrophoresis (Figure 29). The enzyme-resistant oligonu-22 Journal of Nucleic Acids
Table 11: The analysis of [32P]-labeled U2 RNA 5  oligonucleotide [12]. The 5  ends obtained from uniformly [32P]-labeled U2 RNA were
digested with T1 RNase or RNase A and isolated by two-dimensional electrophoresis (cellulose acetate at pH 3.5 followed by DEAE paper
electrophoresis). The 5  oligonucleotides were digested with snake venom phosphodiesterase before and after removal of 3  phosphate with
bacterial alkaline phosphatase. The products were separated as in Figure 27. The radioactivity ratios are listed.
5  fragment from U2 RNA
32P ratio in nucleotide
Pi pUm pAm pm3
2,2,7G pC pCp pG pGp
5  oligo from T1 digestion 1.58 1.33 0.91 0.90 1 1.48
Alkaline phosphatase digested T15  oligo 1.22 1.43 0.98 0.90 1 0.93
5  oligo from RNase A digestion 1.74 1.25 1 1.08 1.50
Alkaline phosphatase digested A 5  oligo 0.93 1.45 0.94 0.77 1
Table 12: Tgs1 interacting proteins [70–72]. The Tgs1 (trimethylguanosine synthase 1) interacting proteins are listed. It is interacting with
proteins involved in many aspects of RNA metabolism such as transcription, spliceosome assembly, maturation, and modiﬁcation.
Tgs interacting proteins [70]
Transcription apparatus (regulators of RNA polymerase II transcription)
(1) Rpn4 (TF; Proteasome subunits and U2 snRNA gene)
(2) Spt3 (SAGA complex)
(3) Srb2 (mediator complex)
(4) Soh1 (Med31; mediator complex)
(5) Swr1 (ATPase; binds to 5  end of yeast transcription units)
(6) Htz1(H2AZ) (binds to 5  end of yeast transcription units)
(7) CBP (binds to human PIMT/Tgs1)
(8) P300 (binds to PIMT/Tgs1)
(9) PBP (binds to PIMT/Tgs1)
(10) PRIP (binds to PIMT/Tgs1; [71])
Spliceosome assembly
(1) Mud1 (yeast homolog of U1A)
(2) Mud2 (yeast homolog of U2AF65)
(3) Nam8 (Mud15) (homolog of TIA-1)
(4) Brr1 (snRNP)
(5) Lea1 (U2A; U2snRNP)
(6) Ist3 (Snu17; U2 snRNP)
(7) Isy1 (Ntc30; interacts with Prp19)
(8) Cwc21 (component of Cef1 complex)
(9) Bud13 (Cwc26) (Cef1 complex)
(10) SMN (HeLa cell) [72]
RNA end processing and decay
(1) Trf4 (Pap2; catalytic subunit of TRAMP)
(2) Lsm1 (decapping complex)
(3) Pat1 (decapping complex)
RNA modifying factors
(1) SmB (snRNP; interacts with
YNL187/Swt21)
(2) SmDL (snRNP)
(3) Cbf5 (snoRNP)
(4) Nop58 (snoRNP)
(5) Mrm (RNA 2 -O-methyltransferase)
cleotides 11A and 11B were eluted from the paper and
treated with alkaline phosphatase. The products were chro-
matographed on DEAE-Sephadex A-25 with GMP, GDP, and
GTPmarkers.The11A(capII)waselutedatGTPregionand
11B(capI)waselutedatGDPregion,indicatingthat11Bhas
one nucleotide less than 11A (Figure 31).
From these data, obtained by UV, [3H], and [32P]
experiments, the U3 RNA 5  oligonucleotide sequence has
been deduced to be m3
2,2,7GpppAmpA(m)pApGpCp.
8.4. 5S RNA III (U5 RNA) 5  End Oligonucleotide. The oligo-
nucleotide sequence was deduced as in the case of U1
RNA. The structure is identical to the U1 5  oligonucleotide
m3
2,2,7GpppAmpUmpApCp.
9. RNA SignatureModiﬁcations for
Different RNA Classes
9.1. End Modiﬁcations
9.1.1. 5  End
(a) According to Chemical Nature of Caps
5  Trimethylguanosine cap for the snRNA,
5  7-mehtylguanosine cap for the mRNA,
5  2,7 dimethylguanosine cap of virus and nematode
RNAs
5  mpppG of U6 RNA.
(b) According to Flanking Nucleotide Modiﬁcation of Caps.
(See Table 13).Journal of Nucleic Acids 23
(c) 5  End Uncapped RNA. (pppNp) for primary transcripts
s u c ha s4 . 5 SR N AI ,5 SR N A ,a n dA l uR N A .( p N p )5   end for
processed RNAs such as Alu RNA, 5S RNA, tRNA, YRNA.
9.1.2. 3  End
3 2 -O-methylated; 4.5S RNA III
3  poly-A; mRNA, lncRNA
3  poly-U; polymerase III transcripts such as 4.5S
R N AI ,5 SR N A ,a n do t h e r s
3  CCA; tRNA, U2 RNA.
9.2. Internal Modiﬁcations. The most colorful modiﬁcations
are in tRNAs that contain methyl, formyl, acetyl, isopentyl,
threonyl, carbamoyl, and other groups and modiﬁcations
by pseudouridylation, deamination, reduction, or thiolation.
Focusing on recent ﬁndings for snRNA, m3
2,2,7G capping
reactions are very interesting because trimethylguanosine is
foundonlyinnoncodingRNAcapstructures,althoughsome
nematode mRNA species also contain m3
2,2,7G caps. The
snRNAs are less abundant (105 copies) than ribosomal RNA
or tRNA (106 copies). Isolating large amount of RNA can
be a hurdle to overcome. Massive preparative procedures
and syntheses were pivotal for the thorough analysis of these
modiﬁcations. The 2 -O-modiﬁcations occur mostly inter-
nally, and 3  Um was also found in 4.5S RNA III. The RNA
ribosewith2 -O-methylationconfersresistancetoenzymatic
digestion by such enzymes as RNase A, RNase T1, RNase U2,
and RNase T2. They are also resistant to alkaline hydrolysis,
and the alkaline hydrolysates can be separated into di-, tri-,
andtetranucleotidesbycolumnchromatographyandthenby
two-dimensional paper chromatography (Figure 16). Other
enzymes which can cleave 2 -O-methylated nucleotides
are snake venom phosphodiesterase, P1 nuclease, and
spleen phosphodiesterase. These are valuable tools for
sequencing.
10. Presence of m3
2,2,7GCapsinRN ASpecies
10.1. Nucleolar RNA. Initially, the m3
2,2,7G cap containing
snoRNAwasfoundinU3RNA[36].SincethenC/DsnoRNA
and H/ACA snoRNA have been discovered exponentially.
The snoRNAs are transcribed from monocistronic as well
as polycistronic independent positions as well as intronic
regions of mRNA, especially the genes coding ribosomal
proteins. In vertebrates, there have been >76 snoRNAs that
have been reported, but only U3, U8, and U13 snoRNAs
have been reported to have m3
2,2,7Gc a p s[ 33, 88]. In yeast,
there are at least 17 m3
2,2,7G cap containing snoRNAs out
of more than 76 snoRNAs. It was also reported that some
snoRNA precursors, such as pre-snoRNAs 50, 64, and 69,
have the m3
2,2,7G cap, but mature snoRNA 50, 64, and 69 do
not have m3
2,2,7G caps. The maturation process cleaves the
5  fragment by Rnt1 (RNase III like enzyme), and trimming
is performed by 5  → 3  exonuclease Xrn1 and Rat 1
[89].
10.2. Spliceosomal snRNAs. These include U1, U2, U4, U5,
and U6 snRNAs. All of these except U6 contain the m3
2,2,7G
cap, and U6 has the mpppG cap instead. They are present
in complexes as RNP with proteins speciﬁc for each RNA
as well as some common snRNP proteins such as the Sm
proteins. Functionally, U1 RNP acts at 5  splice sites and U2
RNA at branch sites including 3  splice sites. U4, U5, and U6
snRNAs enter the spliceosomal intermediate as a tri-snRNP
complex.
10.3. Human Telomerase RNA (hTR). Human telomerase
RNA has a structure containing the H/ACA motif with 8
conserved regions (CR 1–8) [92].The CR7 contains the CAB24 Journal of Nucleic Acids
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Figure 18: HPLC (High Pressure Liquid Chromatography) pattern of nucleosides of 5  o l i g o n u c l e o t i d e so fU 1R N A ,U 2R N A ,a n dU 3
RNA [37]. The 5  oligonucleotides of U1, U2, and U3 RNAs were obtained by digestion of T1 RNase and RNase A. The fragments were
digested with snake venom phosphodiesterase and alkaline phosphatase. The nucleosides produced were separated by high pressure liquid
chromatography (Varian Aerograph Liquid Chromatograph LCS-1000) at 55◦C, 700–800p.s.i. with 0.4M ammonium formate (pH 3.5).
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Table 13: Cap variations of ﬂanking nucleotide modiﬁcations.
Trimethylguanosine cap 7-Methylguanosine cap
Type 0 m3
2,2,7GpppN- m7GpppN-
Type I m3
2,2,7GpppNmN- m7GpppNmN-
Type II m3
2,2,7GpppNmNmN- m7GpppNmNmN-
Type III m3
2,2,7GpppNmNmNmN- m7GpppNmNmNmN-
Type IV m3
2,2,7GpppNmNmNmNmN- m7GpppNmNmNmNmN-Journal of Nucleic Acids 25
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Figure 19: Identiﬁcation of m3
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  [16]. (a) Fluorogram of two-
dimensional thin layer chromatography of [3H]-labeled nucleoside
trialcohol derivative (N
 ) released from U1 RNA 5  fragment.
It was identiﬁed as m3
2,2,7G
  with standard. (b) Fluorogram of
chromatographic separation of [3H]-labeled nucleoside trialcohol
derivative on Whatman 3MM paper. The [3H]-labeled compound
was identiﬁed as m3
2,2,7G
  with standard.
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Figure 20: 2D map of U1 RNA digested with T2 RNase and U2
RNase [16]. The U1 RNA uniformly labeled with [32P] was digested
with T2 RNase and U2 RNase. The resistant 5  fragment (spot “a”)
was separated from the rest of the hydrolysate by two-dimensional
electrophoresis. The ﬁrst dimension was on cellogel at pH 3.5, and
the second dimension was on DEAE paper in 5% acetic acid-NH4
acetate at pH 3.5.
box (Cajal body box) consensus sequence of UGAG and
directs the RNA localization into the CB (Cajal body). The
Tgs1 (trimethyl guanosine synthase) is also present in the
Cajal body and may be responsible for the m3
2,2,7Gc a p
formation. Not all Cajal bodies contain the hTR, and it
may be a transient localization for the maturation of hTR
in the Cajal body. In the absence of Tgs1, the telomere of
yeast S. cerevisiae has elongated single-stranded 3  overhangs
and TLC1 (1200nt telomerase RNA) lacks the m3
2,2,7G
cap. The absence of Tgs1 causes premature aging of yeast
[93, 94].
10.4. C. elegans SL RNA. C. elegans has mRNA with the
m7G cap as well as m3
2,2,7G cap, and the expression is
regulated diﬀerentially. The genes for protein coding are
monocistronic as well as polycistronic, and introns are much
smaller than observed in mammalian cells. The polycistronic
genes contain 2–8 operonic genes regulated by the same
promoters. Some gene products are not processed, and
others are spliced by cis-splicing as well as transsplicing. The
transsplicings are carried out by SL RNA 1 or SL RNA 2.
The approximately 110 SL RNA 1 genes are in tandem in
chromosome V. The SL RNA 2 is derived from SL RNA 1
and there are ∼18 dispersed genes with a variety of variant
SL2 RNAs (some are called SL3, SL4, etc.). They are all
100–110 nucleotide long and contain m3
2,2,7Gc a p sa n d
Sm protein binding sites. These pre-mRNAs, containing 5 
outron (monocistronic and 5  ﬁrst gene in polycistronic
operonic genes), are transspliced by SL RNA 1 and internal
operonic pre-mRNAs are mostly transspliced by SL RNA 2
and these genes have typically U-rich sequence containing
∼100bp spacers between two cleavage sites. The internal
mRNAgeneofpolycistronicoperonicgenes,lackingaspacer,
is transspliced always by SL RNA I [95, 96]. The transspliced
mRNA contains a m3
2,2,7G cap containing 22 nucleotides of
SLRNAattheir5  ends.TheSLRNA(spliceleaderRNA)has
am 3
2,2,7G cap and Sm protein binding sites. The nematode
C. elegans has 5 eIF4E isoforms of cap binding proteins. They
are IFE-1 (m7G cap and m3
2,2,7G cap binding), IFE-2 (m7G
cap binding, but competed by the m3
2,2,7Gc a p ) ,I F E - 3( m 7G
cap binding only), IFE-4 (m7G cap binding only), and IFE-
5( m 7G cap and m3
2,2,7G cap binding). The homolog amino
acids W56 and W102 stacking the m7G caps in mice eIF4E
are W51 and W97 in IFE-3 and W28 and W74 in IFE-5
(Figure 32).
The diﬀerences in 3-4 loop conﬁguration between IFE-
5 and IFE-3 are N64Y/V65L. The changes in IFE-5 amino
acid asparagine 64 to tyrosine and valine 65 to leucine
change binding properties more to m7G cap binding than
to m3
2,2,7G cap binding. IFE-5 has 4 cysteines, and its
conformation is governed by disulﬁde bond formation. It is
suggested that the cap binding cavity is altered to produce
a smaller cavity that discriminates against the m3
2,2,7Gc a p
binding [85]. These may provide translational regulation of
m7G cap mRNA and transspliced m3
2,2,7Gc a pm R N Ai n
C. elegans.26 Journal of Nucleic Acids
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11.Synthesis of m3
2,2,7GCap
modiﬁcations. Trimethyl G caps are present in snRNAs
involved in splicing and also in snoRNA involved in
rRNA processing and modiﬁcations such as Ψ formation
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The peak from the GTP region was digested with snake venom
phosphodiesterase and separated on Whatman 3MM paper by
electrophoresis at pH 3.5 (5% acetic acid adjusted pH to 3.5 with
ammonium hydroxide) and chromatography in the second dimen-
sion with a solvent system consisting of isopropyl alcohol, HCl, and
H2O in the ratio of 680:176:144 by volume. Autoradiography was
performed using X-ray ﬁlm.
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Figure 23: Cap core chromatography [16]. The 5  oligonucleotide
eluted from the GTP region (Figure 21) was digested with P1 RNase
and chromatographed on a DEAE-Sephadex A-25 column. Two
peaks “a” (mononucleotides pUm and pA) and “b” (cap core
m3
2,2,7GpppAm) were observed.
(H/ACA snoRNA) or 2 -O-methylation (C/D snoRNA).
These include U1, U2, U4, and U5 spliceosomal RNAs,
and U3, U8, and U13 nucleolar RNAs. Recently, telomerase
RNA (S. cerevisiae TLC1) has also been reported to haveJournal of Nucleic Acids 27
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a trimethylguanosine cap structure. The trimethyl-G caps
are formed on cap 0 or cap I of m7Gc a p so fp r e -
snRNAs by dimethylation of N2 position by trimethyl-
guanosine synthase (Tgs1). The Tgs1 has been found to
be in the Cajal body and cytoplasm. The U3 snoRNA is
hypermethylated in the Cajal body, and U1, U2, U4, and
U5 snRNA have been reported to be hypermethylated in
the cytoplasm.
11.1. The m7G Cap Formation. The RNA polymerase initi-
ates the RNA transcription with 5  triphosphate nucleotides
and in a majority with purine nucleotides of ATP or GTP.
The capping reaction in a polymerase II system occurs
cotranscriptionally within the nascent transcript of ∼30–50
nucleotides. The guanylyltransferase is attached to heptad
(YSPTSPS) repeats of CTD of RNA polymerase II. It
was reported with cloned mouse guanylyltransferase and
synthetic heptad repeats that the serine 5 phosphorylated
6 heptad repeats stimulated guanylyltransferase activity 4-
fold. Serine 2 phosphorylation also binds the guanylyl-
transferase but did not stimulate enzyme activity [97].
The capping enzymes contain RNAtriphosphatase and RNA
guanylyltransferase in the same molecule, but methylating
enzymes are in diﬀerent protein and occurs in separate
steps.
The enzymes involved are RNA triphophosphatase and
RNA guanylyltransferase, which can be found in the same
enzyme, catalyze removal of one phosphate from pppNp
initiation nucleotide, and transfer GMP from GTP through
intermediary GMP-lysine phosphamide enzyme complex.
The RNA guanyl 7 methyltransferase methylates the guanine
at N7 position. The RNA 2 -O-methyltransferase methylates
penultimate nucleotide 2  OH, producing the cap 1 struc-
ture. In rat liver, it has been reported that 2 -O-methylation
may precede the guanosine N7 methylation [98].
The capping reactions by mammalian and shrimp cap-
pingcomplexes(HeLacell,ratliver,calfthymus,andshrimp)
[98] have been reported as below:
RNA Triphosphatase and Guanylyltransferase. The monomer
of the 69–73kDa protein has functions of RNA triphos-
phatase and RNA guanylyltransferase activity.
pppNpNpNpNp-
RNA triphosphatase
− −−−−−−−−−−→ ppNpNpNpNp- (1)
GTP+RNA guanylyltransferase
Mg++
− −−→ GMP-
 
phosphamide
 
-E +ppi (2)
GMP-E+ ppNpNpNpNp-
Mg++
− −−→ GpppNpNpNpNp- + RNA guanylyltransferase (3)
GpppNpNpNpNp- + AdoMet
RNA 2 -O-methyltransferase
− −−−−−−−−−−−−−−− → GpppNmpNpNpNp- + AdoHcy (4)
GpppNmpNpNpNp- + AdoMet
RNA guanyl 7-methyltransferase
− −−−−−−−−−−−−−−−−− → m7GpppNmpNpNpNp + AdoHcy (5)Journal of Nucleic Acids 29
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Figure 26: Fluorograph of [
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2,2,7Gf r o mU 2R N A5   end [12]. (a) Two-dimensional thin layer
chromatography. (b) One-dimensional paper chromatography. In both systems, the labeled compound was m3
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Some of the capping enzymes (vesicular stomatitis virus,
spring viremia of carp virus) use the substrate monophos-
phorylated 5  end (pNpNpNpNp-) [99, 100], and 7-
methylation occurs after the 2 -O-methylation has taken
place.
Trimethylguanosine cap synthesis is carried out by mul-
tiple steps involving From HeLa cells, two enzymes forming
cap I from cap 0 and cap II from cap I have been puriﬁed and
characterized [101].
11.2.CapIMethyltransferase. This enzyme is presentin both
the nucleus (29.3units/mg) and cytoplasm (3.74units/mg)
and cap II methyltransferase is exclusively in the cytoplasm
(4.62units/mg). Cap I methyltransferase uses GpppA(pA)n,
m7GpppA(pA)n,m 7GpppApGp, m7GpppApGpUp, and
R N Aw i t ht y p e0c a pa ss u b s t r a t e sb u tn o tm 7GpppA or
GpppA. The substrate required for cap I formation should
be at least a trinucleotide.
The order of 7-methylation of ultimate G nucleotide and
2 -O-methylation of penultimate nucleotide is uncertain,
and both pathways may occur.
11.3. Cap II Methyltransferase. This enzyme is present only
in the cytoplasm and converts cap I to cap II. The mature
mRNA with 5  m7G cap and 3  polyadenylation is then
transported into the cytoplasm as a complex with CBC20/80,
PHAX, and Crm1-RanGTP. The m7G cap binds to CBC20
(156 amino acids) in complex with CBC80 (790 amino
acids). The crystal structure of the CBC20/80 complex in
association with m7G cap has been reported [86, 87]. The
CBC20 is in an unfolded form in the absence of CBC80.
The CBC80 has 3 domains, each containing consecutive 5-
6 helical hairpins resembling the MIF4G (middle domain
of eIF4G). The CBC20 has a typical RRM motif and binds
b e t w e e nd o m a i n s2a n d3o fC B C 8 0 .T h em 7Gc a pi s
sandwiched between Tyr 43 and Tyr 20. And Phe 83, Phe 85,
andAsp116haveessentialroleform7Gcapbinding.Asp116
and Trp 115 interact with the N2 amino group and confer
speciﬁcity of the m7Gc a pf o ro t h e rs t r u c t u r e s( Figure 33).
In the cytoplasm, the m7G cap plays a role in the
initiationoftranslationbybindingtoeIF4Ewhichcomplexes
with eIF4A and eIF4G. The exact mechanism of exchange is
not known but CBC80 has binding capacity for PHAX or
eIF4GanddissociationofCBC80fromCBC20makesCBC20
become disordered [86, 87].
11.4. Maturation of snRNAs. The snRNAs synthesized by
R N Ap o l y m e r a s eI Iw i t hm 7G cap structures are transported
intothecytoplasmincomplexwithCBP20/80,PHAX(phos-
phorylated adaptor for RNA export), the CRM1 (export
receptor, chromosome region maintenance 1) or exportin 1
and RanGTP (Ras-related nuclear antigen). The snRNPs in
the cytoplasm are trimethylated and processed. The mature
RNA is reimported into the nucleus in a complex with the
trimethyl G cap-speciﬁc binding protein snurportin 1 and
snRNA binding proteins of Sm RNP and SMN proteins.
Despite immunoﬂuorescent staining of U1 and U2 RNA
exclusively in the nucleus [102], biochemical analyses have30 Journal of Nucleic Acids
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Figure 27: Autoradiograph of nucleotides from [32P]-labeled U2
RNA 5  fragment [12]. The [32P]-labeled U2 RNA 5  fragment
(T1 RNase digestion) was treated ﬁrst with alkaline phosphatase
and then with snake venom phosphodiesterase. This mixture
of mononucleotide products was separated by electrophoresis
followed by chromatography. Approximately equal amounts of
pm3
2,2,7G, pAm, pUm, pC, and pG were observed (Table 11).
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Figure 28: The susceptibility of 5  cap to pyrophosphatase [12].
The [32P]-labeled 5  oligonucleotide obtained from U2 RNA by
RNase A was digested with pyrophosphatase and base composition
was analyzed by snake venom phosphodiesterase digestion. This
digestion released m3
2,2,7G from the 5  fragment indicating that
m3
2,2,7G is linked by a pyrophosphate linkage.
demonstrated that trimethylation and maturation of some
snRNA takes place in the cytoplasm.
The U1 snRNA [103] and U2 snRNA [104]h a v eb e e n
shown to be hypermethylated in the cytoplasm in a Sm
protein binding dependent manner. The Xenopus laevis U1
RNA, with the m7G cap, has been shown to be hypermethy-
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Figure 29: 2D map of U3 RNA digest [58]. The [32P]-labeled U3
RNA was digested with T2 RNase and U2 RNase. It produced two
5  fragments “11A” and “11B”.
latedinHeLacellcytoplasmicextractsandSmbindingsitein
U1 RNA is required [103]. The Tgs1 has been shown to bind
to Sm proteins of Sm B and Sm D. The Xenopus laevis U2
RNA with m7G cap has been shown to be hypermethylated
intothem3
2,2,7Gcapstructureinenucleatedxenopusoocytes
[104]. In yeast and human HeLa cells, the Tgs1 for U3
RNA is localized in the nucleolar body of the nucleolus
and Cajal bodies, respectively [105]. In the absence of Tgs1
or inactive Tgs1 in yeast, m7G capped unprocessed U1
RNA is retained in the nucleolus and splicing becomes
cold temperature sensitive. The same enzyme is responsible
for the U3 nucleolar RNA hypermethylation [106]. The
consensus between yeast and human cells is the presence of
a nucleolar body in yeast and Cajal body in HeLa cell. The
hypermethylation and processing during maturation take
place in the nucleolar body in yeast and Cajal body in HeLa
cells [105, 106]. The sequence element “UGAG” (also found
intheU3RNABbox)hasbeenreportedasaCABbox(Cajal-
body-speciﬁc localization signal). U3 RNA trimethylation
is somewhat diﬀerent from other snRNAs. The U3 RNA,
which does not have Sm protein binding sites, has been
shown to require an intact 3  terminal stem structure for
trimethylguanosine cap formation [107].
In HeLa cells, transfected U3 RNA gene products are
trimethylated and mature U3 RNA is localized in the nucle-
olus. Immature U3 RNA, with both m7Ga n d3   extension of
10–15 nucleotides, is detected in Cajal bodies. The nucleolar
localization requires the CAB box, hypermethylation to
m3
2,2,7G cap, and maturation of the 3  end [105]. Unlike U1
RNAandU2RNA,U3RNAhasbeenshowntoberetainedin
thenuclearcompartmentanddoesnotgointothecytoplasm
for its trimethylation reaction [105, 106, 108].
12.The Tgs1 (TrimethylguanosineSynthase 1)
12.1. Human Tgs1. The Tgs1, trimethylguanosine synthase
in human, protein is 110kDa and 852 amino acids in chainJournal of Nucleic Acids 31
l e n g t h .T h eg e n ei sl o c a t e di nc h r o m o s o m e8 q 1 1 .T h em R N A
is 3.2kb in length and produces a 110kDa protein and ∼65–
70kDa protein that is proteasome processed. The long form
is in the cytoplasm, and the short isoform has been reported
tobelocalizedintheCajalbodywithinthenucleus.TheTgs1
has S-AdoMet methyltransferase signature motifs of X, I, II
(include post 1 motif), III, IV, V, and VI [70, 106, 109, 110].
The human Tgs1 motifs are the following.
motif X is (a.a.665)DREGWFSVTPEKIAEHI/FA(a.
a.682),
motif I is (a.a.693)VVVDAFCGVGGN(a.a.704),
motif II is (a.a.714)RVIAIDIDPV/IKI(a.a.725) and
post 1 motif is VIAID which is responsible for S-
AdoMet binding to the enzyme,
motif III is (a.a.740)KIEFICGDFLLLAS(a.a.753),
motif IV is (a.a.758/759)VVFLSPPWGGPDYA(a.a.
771/772),
motif V is (a.a.785/786)DGFEIFRLSK(a.a.794/795),
motif VI is (a.a.798/799)NNIVYFLPRNADI(a.a.810/
811),
It was reported that trimethylation catalytic activity is
located in the C-terminal region (amino acids 631–852) and
this region contains the S-AdoMet-dependent methyltrans-
ferase motifs. The tryptophan in motif 4 is involved in π
stacking with m7G guanosine of the substrate. The motif 1
and post 1 motif are reported to interact with S-AdoMet.
[110]. The C-terminal domain is localized in the Cajal body
and binds to C/D-snoRNA- and H/ACA-snoRNA-associated
proteins such as ﬁbrillarin, Nop56, as well as dyskerin [110].
The N-terminal portion of the molecule (amino acids
1–∼477) has been reported to contain GXXGXXI, a K-
homology domain for RNA binding, and a motif for SmB
and SmD1 binding. The Tgs1 has also been shown to inter-
act with PRIP (proliferator-activated receptor-interacting
protein), and the N-terminal portion (amino acids 1–384)
of Tgs1 has been shown to have stimulatory eﬀects on
transcription of PPARγ and RXRα [109, 110].
The human Tgs1 (618–853) has been crystallized for
structural analysis. The one monomer consists of 11 α-
helicesand7β-strands.Itiscomposedof2domains,thecore
domain(Glu675-Asp844)andN-terminalextension(Leu34-
Ser671) connected by 3 amino acids—Val672, Thr673,
and Ser674. The core domain consists of 7-β-strands in
topology of β6↑β7↓β5↑β4↑β1↑β2↑β3 ↑ with a classical
class 1 methyltransferase fold resembling the Rossmann-
fold AdoMet-dependent methyltransferase superfamily [90].
The N-terminal α-helices form a separate small globular
subdomain involved in recognition and binding of both
substrates. The residues Glu667 and Phe670 in motif X as
well as Pro765, Trp 766, and Pro769 in motif IV are in
proximity permitting the top of their binding clefts to be
close together. Tryptophan 766 and m7G are stacked in a
coplanar manner with a 3.2 ˚ A distance providing a tight π-
π interaction between them (Figure 34).
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Figure 30: m3
2,2,7G
  identiﬁcation from U3 RNA 5  end fragment
[58]. The [3H]-labeled U3 RNA 5  fragment obtained by RNase T1
andRNaseAwasdigestedwithsnakevenomphosphodiesteraseand
alkalinephosphatase.Thenucleosidemixturewasseparatedbytwo-
dimensional thin layer chromatography with standard nucleoside
mixture in (a) and with the trialcohol derivative of m3
2,2,7G
  in
(b). The released nucleoside trialcohol derivative was identiﬁed as
m3
2,2,7G
  by ﬂuorography.
The catalytic mechanism of methylation is by an Sn2
substitution reaction. The N2 of m7G does the nucleophilic
attack on an activated methyl group of the AdoMet
(Figure 35).
Dimethylation is not processive. After formation of
m2
2,7Gb o t hp r o d u c t s( m 2
2,7G and AdoHcy) dissociate from
the enzyme. Tgs1 can use m2
2,7G as a substrate, and newly
bound AdoMet can methylate at the same position by the
same mechanism to form the m3
2,2,7Gc a ps t r u c t u r e .32 Journal of Nucleic Acids
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Figure 3 1 :U 3R N Ac a pIa n dc a pI Ic h r o m a t o g r a p h y[ 58]. The
5  fragment from Figure 29 was eluted and treated with alkaline
phosphatase and chromatographed on DEAE-Sephadex A-25 with
standards of GMP, GDP, and GTP. Component “11B” was eluted
in the GDP (cap I, m3
2,2,7GpppAmA) region and “11A” (cap II,
m3
2,2,7GpppAmAmA) was eluted in the GTP region.
12.2. Drosophila Tgs1. In Drosophila melanogaster, DTL
(Drosophila TAT-like) has been reported to exhibit
trimethylguanosine cap formation activity for both U2 and
U4 snRNAs. The mRNA for the protein Tgs1 is polycistronic
and 2,600-nucleotide long with upper and downstream
ORFs (open reading frames). The uORF is 80bp from the
transcription start site and has coding capacity for a 178
amino acid protein while dORF is 538bp from the 5  end
and produces a 60kDa protein (491 amino acids). The two
cistrons are overlapped by 76bp. Mutational analysis in-
dicates that both the uORF and dORF regions are required
forviability. Theputative product ofuORFcontains periodic
Leu residues, but there is no evidence that this region is
translated at any time during Drosophila development.
The protein from dORF contains an Arg-rich motif KKKR-
RQRQI similar to the RNA binding motif RKKRRQRRR
in HIV TAT. This protein is localized in the nucleus and
responsible for trimethylation of U2 and U4 snRNAs
[111].
12.3.YeastTgs1. InyeastS.cerevisiae,Tgs1isinthenucleolus
and U3 RNA is also in the nucleolus. In the absence of Tgs1,
the pre-U3 RNA was found within the nucleolar body and
U1 RNA was retained in the nucleolus. S. cevisiae, S. pombe,
and Giardia lamblia Tgs1 can methylate m7GTP, m7GDP,
and m7GpppA as substrates without preassembly of snRNP
containing Sm proteins. The Tgs1 of S pombe is 239-amino-
acidlongandm7Gisthepre-requisiteforthisreaction[112].
12.4. The G. lamblia Tgs1 and Tgs2. The lamblia has 2 en-
zymes, Tgs1 and Tgs2. Tgs 1 is not a processive enzyme but
distributive and produces m3
2,2,7Gi ne x c e s so fA d o M e ta n d
enzyme. However, Tgs2 produces only m2
2.7G, and some G.
lamblia RNAs contain dimethylG caps. The G lamblia Tgs1
has 300 amino acids and Tgs2 is 258 amino acids long. They
all have landmark motifs for Ado-Met-dependent methyl-
transferase motifs [113].
13.ParasiteCappingEnzyme
(Trypanosoma brucei)
The parasite Trypanosoma brucei SL RNA (splicing
leader) has the biggest 5  oligonucleotide, type IV, of
m7Gpppm2
6,6AmpAmpCmpm3UmpAp [114, 115]. En-
zymes involved in the synthesis of this cap structure
are TbCgm1, TbCet1, TbMTr1(cap1 2 OMTase), TbMTr2/
TbCom1/TbMT48(cap2 2 OMTase), TbMTr3/ TbMT57(cap3
2 OMTase). However, m2
6,6Aa n dm 3Um methylating en-
zymes have not been identiﬁed as yet [115].
13.1. TbCgm1 (T. brucei Cap Guanylyltransferase Methyl-
transferase 1). There exist two enzyme systems for 5  cap
formation.Theﬁrstisthesystemcomposedofseparateinde-
pendent enzymes which are TbCet1 (Trypanosoma brucei
triphosphatase, 253 amino acids), TbCe1 (Trypanosoma
brucei guanylyltransferase, 586 amino acids), and TbCmt1
(Trypanosoma brucei m7G Cap methyltransferase 1, 324
amino acids). The second is a set of fused enzymes possess-
ing dual activities. It is TbCgm1 (Trypanosoma brucei cap
guanylyltransferase and methyltransferase 1) that has 1050
amino acids [116] with dual activities of guanylyltransferase
and guanine N-7 methyltransferase [117]. The TbCe1 guan-
ylyltransferase has 250 amino acids at its N-terminal region
whichisnotfoundinfungalormetazoanguanylyltransferase
and has homology with the phosphate binding loop found in
ATP- and GTP-binding proteins [118]. Silencing TbCe1 and
TbCmt1 had no eﬀect on parasite growth or SL RNA
capping, but TbCgm1 was essential for parasite growth and
silencing TbCgm1 increased the amount of uncapped SL
RNA. The protein TbCgm1 has guanylyltransferase activity
in N-terminal 1–567 amino acids and methyltransferase
activity in C-terminal 717–1050 amino acids. The N-
terminal guanylyltransferase portion contains 6 colinear
guanylyltransferase motifs: I(KADGTR), III(FVVDAELM),
IIIa(LIGCFDVFRYVI),IV(DGFIF),V(QLXWKWPSMLSVD),
and VI(WSIERLRNDK). The C-terminal methyltransferase
por-tion contains regions homologous to m7G methyltrans-
ferase from T. cruzi and L. major [117].
13.2. Cap Methylating Enzymes: TbMTr1, TbMTr2(TbCom1/
TbMT48), and TbMTr3(TbMT57). They contain a K95-
D207-K248-E285 tetrad critical for AdoMet-dependentJournal of Nucleic Acids 33
Figure 32: Molecular models of IFE-3, IFE-5, and IFE-5 (NV-YL) in comparison with mouse eIF4E [85]. The diﬀerences between the m7G
cap binding pocket and m3
2,2,7G cap binding pocket are illustrated by diﬀerences in the 3-4 loop conﬁguration.
Figure 33: CBP20 (cap binding protein 20) binding to m7Gc a p[ 86, 87]. The m7G is stabilized by stacking energies between tyrosine 20 and
tyrosine 43.
methyltransferaseandcanconvertcaptype0ofTrypanosoma
SL RNA and U1 snRNA into type 1 cap [115]. The KDKE
mediates Sn2t y p et r a n s f e ro fm e t h y lg r o u p st h a ti n v o l v e
2 -OH deprotonation. The U1 snRNA 2 -O-methylation
takes place before Sm protein binding to the RNA and it
is prerequisite for the dimethylation at the N2 position
to make m3
2,2,7GpppAm cap structures. Other m3
2,2,7G
cap-containing snRNAs such as U2, U-snRNA B (U3 snRNA
homolog), and U4 snRNAs were reported to be synthesized
b yR N Ap o l y m e r a s eI I Ii nTrypanosomes.
The TbMTr2 and TbMTr3 are responsible for second and
third nucleotides 2 -O-methylations. The enzymes that per-
form m2
6,6A, m3U base methylations, and fourth nucleotide
2 -O-methylating enzymes are not known yet.34 Journal of Nucleic Acids
(a) (b) (c)
Figure 34: Crystal structure of hTgs1 [90]. The crystal structure of hTgs1 with substrate m7GTP and AdoHcy (at the site for AdoMet). The
m7G is stacked between tryptophan 766 and serine 671 [90]. (a) Relative orientation of substrates m7GTP and AdoHcy at binding pockets.
(b) Detailed view of the binding pocket for m7GTP (shown W766 and S671). (c) Detailed view of the binding pocket for AdoHcy.
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Figure 3 5 :T h ea c t i v es i t eo fh T g s 1[ 90]. Proposed mechanism of methyltransferase activity of hTgs1 is shown. The AdoMet methyl group
is in close proximity to N2 position of m7GTP. The prerequisite as a substrate for hTgs1 is m7Gm o i e t y .
14. Transport of MatureRNAs
The snurportin1 is a speciﬁc trimethyl G cap binding pro-
tein with an importin β binding site at its N-terminus
(amino acids 1–65) and trimethyl G cap binding site at
amino acids 95–300 forming a cap binding pocket. This
protein has more resemblance to mRNA guanylyltransferase.
The snurportin 1 binds the trimethyl G cap forming π-
stacking with tryptophan 276 and the penultimate purine
nucleotide G (Figure 36). The tryptophan 107 is in close
proximity to dimethylamine of N2 G suggesting a cation-π
interactionandhasaroleindiscriminatingbetweenm7Gcap
and m3
2,2,7Gc a p[ 91].
15.Tgs 1InteractingProteins
GeneticandbiochemicalanalysisofTgs1interactingproteins
revealsawiderangeofproteinsinvolvedinRNAmetabolism.Journal of Nucleic Acids 35
Snurportin1
Ser105
Trp107
Leu104
Trp276
m3GpppG
Tyr20
Asp116
CBP 20
Trp115
Asp114
Arg112
Tyr43
m7GpppG
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eIF4E
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Trp56
m7Gpp
m7Gppp
Tyr22
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Figure 36: The comparison between m3
2,2,7G binding mode to snurportin1 and m7G cap binding mode to CBP 20, eIF4E and VP39 [91].
The m3
2,2,7G is stacked between tryptophan 107 and penultimate nucleotide G of cap core m3
2,2,7GpppG.
pppGGUCGAGAGG AUGGCUCAGC CGUUAA GC UAGGCCAAAA AUAA{CACCUA 
U}AAGAGUUCG GUUCCC AG CA CCACGGCUGU CCUUCCAGCA CCUUUU-OH  []
AG []
Figure 37: The sequence of 4.5S RNA I (Novikoﬀ hepatoma cell nuclei).
It interacts with proteins in the transcriptional apparatus,
RNA end processing and decay, spliceosomal assembly and
RNA modifying factors (Table 12).
Structurally, it is distinct from the m7G cap, and the
speciﬁcity of binding proteins may determine the precision
of its functional role in the RNP complex. The m3
2,2,7G
cap structures are present only in nuclear snRNAs and
snoRNAs which confer the function within the nucleus
in transcription, splicing, modiﬁcation, processing, and
maturation of diﬀerent RNA species.
16. Conclusion
16.1. General Consideration. In the present postgenomic
era, study of the structure and function of noncoding
RNAs is supremely important. It is estimated that ncRNAs
are probably involved in all aspects of cell metabolism.
Therefore, RNA-based information will contribute greatly to
understanding various cell metabolisms. In the process of
exploring ncRNAs, there may be many surprises awaiting us.
They may include
(1) new species of RNA,
(2) new mechanism of RNA processing,
(3) new mechanism of transcription,
(4) new disease caused by RNAs with pathogenic se-
quences,
(5) new function for ncRNA.
16.2. The Problem of Unknown Modiﬁed Nucleotides. In
the process of oligonucleotides cataloging, it is natural
that an examination of base composition will reveal mod-
iﬁed nucleotides or nucleosides in addition to unmodi-
ﬁed standard nucleotides or nucleosides. In routine work,
identiﬁcation of modiﬁcations can be readily made by36 Journal of Nucleic Acids
two-dimensional paper chromatography for nucleotides or
thin layer chromatography for nucleosides. However, there
may be an occasion where chromatographic identiﬁcation is
not suﬃcient. Of course, it is best to have collaboration with
outside specialists. For the sake of structural microanalysis, it
is highly recommendable to determine molecular weight of
the unknown nucleotide or nucleoside by mass spectrometry
[119]. The required quantity is approximately 5μg/nt where
chromatographic identiﬁcation of isotopically labeled sam-
ple requires 0.5μg/nt. A diﬃculty may be confronted with
purine bases that are fused to an imidazole ring (Queuosine)
which is not suited for mass spectrometry. It is convenient
to probe chemical complexity based on mass. The detailed
analysis may require an unpredictably large amount of
samples. There are 135 modiﬁed nucleosides listed, among
which 6 nucleosides are not thoroughly identiﬁed [1].
16.3. Signiﬁcance of Sequence Work. Past sequence work has
permeated numerous signiﬁcant areas of research providing
a better understanding of cellular metabolism. The informa-
tion obtained thus far is RNA-based information which is
not seen in DNA, proteins, and others. As sequence work
continues to make enormous progress, the postgenomic era
will shape the direction of research in the area of molecular
mechanisms of RNA metabolism. They are brieﬂy as follows.
In RNA maturation, knowledge of structural modiﬁca-
tions is necessary to discern between various mechanistic
options. For example, there are two molecular mechanisms
mediated by catalysis. One is mediated by RNA enzymes
(snRNAs and snoRNAs) involved in splicing of pre-mRNA
and processing of pre-rRNA. The other is protein enzymes
involved in 5  cap formation. Currently, the higher order
structural analysis is in progress. There is a need to elucidate
the details of molecular mechanisms.
Along with the study of splicing physiology, splicing
pathology is making signiﬁcant progress. Aberrant modiﬁ-
cations can generate disease causing alterations in structure.
The aberrations cause problems in reading both genetic
codes and splicing codes. Studying the regulation of alterna-
tive splicing will clarify the selective rules in intron removal
and pathogenic rules in splicing code. From these studies,
corrective strategy will evolve. The present sequence work
is engaged in deﬁnition of ncRNAs diversity and their
functional roles [120] .S i n c ei ti ss u g g e s t e dt h a tn c R N A s
are involved in all aspects of regulations in cell metabolism,
there may be opportunities to study various paths in cell
metabolism, not limited to transcriptional and posttran-
scriptional events. It is this gigantic task, to reevaluate the
genomic work, that holds excitement and promise.
AbbreviationsUsed in Table 4
Short Noncoding RNA (Usually Shorter Than tRNA and Some
Are Longer but Excluding snRNA Such As U1–U13)
miRNA: MicroRNA (imperfect base pairing)
siRNA: Small interfering RNA (perfect base pairing)
tasiRNA: Transacting small interfering RNA
natsiRNA: Natural antisense transcribed small
interfering RNA
piRNA: PIWI interacting RNA (RNA precipitated by
PIWI protein antibody)
rasi RNA/pitRNA: Repeat-associated small
interfering RNA/pi-target RNA
PARs: promoter associated RNAs
PROMTs: Promoter upstream transcripts
(sense and antisense transcript)
PASRs: Promoter-associated small RNAs
TSSa-RNAs: Transcription-start-site-associated
RNAs
tiRNAs: Transcription initiation RNAs
MSY-RNA: MSY2-associated RNAs (MSY; Y chro-
mosome male-speciﬁc protein)
snoRNA: Small nucleolar RNA (C/D box RNA,
H/ACA RNA)
sdRNA: sno-derived RNAs
moRNA: MicroRNA-oﬀset RNAs
tel-sRNA: Telomere small RNAs
crasiRNA: Centrosome-associated small interfering
RNAs
hsRNA: Heterochromatin small RNA or hairpin
small RNA
scaRNAs: Small Cajal-body-associated RNAs
Y RNAs: Cytoplasmic small RNA Y1, Y3, Y4, and Y5
tRNA-derived RNAs: Small RNA processed from
tRNA by RNase (angiogenin)
Alu/SINE RNA: Alu restriction enzyme cleaved
repeat gene transcript/short interspersed nucleotide
element RNA.
Lnc RNA: Long Noncoding RNA (∼0.5 to 100kb)
(1) Speciﬁc Long Noncoding RNA
TR/TERC: Telomerase RNA/telomerase RNA com-
ponent
NEATRNAs:Nuclearenriched abundanttranscript1
RNAs
NEAT1v-1: NEAT1 variant 1
NEAT1v-2: NEAT1 variant 2
NEAT2/MALAT1: Metastasis associated in lung
adenocarcinoma transcript 1
PINC RNA: Pregnancy-induced noncoding RNA
DD3/PCA3: Prostate-cancer-associated RNA 3
PCGEM1: Prostate cancer gene expression marker 1
SPRY4-1T1: Sprouty homolog 4 gene transcript 1
(melanoma speciﬁc).Journal of Nucleic Acids 37
(2) Imprinting-Associated lncRNAs
xiRNAs: X chromosome inactivating RNAs
Xist: X chromosome inactivating sense RNA
Tsix: Antisense transcript of Xist
RepA: Repeat A RNA
AIR RNA: Igf2r imprinting region RNA
H19: Igf2 imprinting region RNA
KCNQ1ot1: Antisense RNA from intron 10 of Kcng1
gene imprinting region.
(3) Regulatory lncRNAs
HOTAIR: Homeogene inactivating RNA
BORG: BMP/OP-responsive-gene-associated RNA
CTN RNA: Cationic amino acid transporter protein
coding region RNA
ANRIL RNA: Antisense noncoding RNA in INK4
locus.
(4) Gene-Recombination-Associated lncRNA
LINE: long interspersed nucleotide element
CSR-RNA: Immunoglobulin class switch recombina-
tion region RNA.
(5) Satellite DNA Transcripts.
Abbreviations for Table 12
Mud: Mutant U1 die
RES complex: Heterotrimeric RNA retention and
splicing complex composed of Bud13, Ist3/Snu17,
and Pml1
Swt21: Synthetic with Tgs1 number 21
TRAMP complex (Trf4, Air2, Mtr4p polyadenylation
complex): Interacts with exosome in the nucleus and
involved in 3  end processing of rRNA, snoRNA, and
U1, U4, and U5 snRNA;
Trf4 or Trf5: poly(A) polymerase(PAP);
Mtr4: RNA helicase;
Air1 or Air2: Zinc knuckle protein
Cbf5(YLR175W): Centromere binding factor;
Pseudouridine synthase catalytic subunit of box
H/ACA snoRNP complex
PIMT: PRIP-interacting protein with methyltrans-
ferase domain, PIMT is a Tgs1 (trimethylguanosine
synthase 1) cloned from human liver cDNA library
PRIP: PPAR interacting protein
PPAR: Peroxisome proliferator-activated receptor
PBP: PPAR binding protein.
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